INIBIDORES E DEGRADADORES DA PROTEÍNA PIP4K

BR112025024358A2Pending Publication Date: 2026-11-10LARKSPUR BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024358
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-05
Filing Date
2024-05-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Dysregulation of the PI5P4K signaling pathway is linked to various diseases such as diabetes, neurodegenerative disorders, and cancers, and current methods for inhibiting PI5P4K kinase activity or degrading PI4P4K proteins are limited in therapeutic effectiveness.

Method used

Development of compounds that inhibit or degrade PIP4K2A, PIP4K2B, and PIP4K2C proteins, specifically targeting these enzymes to modulate their activity or levels, using a pharmaceutical composition that includes specific chemical formulas and their salts, which recruit the ubiquitin/proteasome system for protein degradation.

Benefits of technology

The compounds effectively reduce the activity or levels of PIP4K2 enzymes, providing therapeutic potential for diseases associated with these proteins, including enhanced immune function and reduced tumor growth, while avoiding the limitations of traditional small molecule inhibitors.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are compounds and compositions of Formula (I'): which modulate the level or activity of PIP4K2A, PIP4K2B, or PIP4K2C. Also provided are methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of PIP4K2A, PIP4K2B, or PIP4K2C, comprising administering the compounds and compositions.
Need to check novelty before this filing date? Find Prior Art

Description

220232001540 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 465,458, filed May 10, 2023; U.S. Provisional Application No. 63 / 611,367, filed December 18, 2023; and U.S. Provisional Application No. 63 / 575,561, filed April 5, 2024; the contents of which are hereby incorporated by reference in their entirety for all purposes. BACKGROUND

[0002] The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks), consisting of the three isoforms, PI5P4Kα, β, and γ, are lipid kinases that catalyze phosphorylation of phosphatidylinositol 5-phosphate (PI5P) on its 4-position to form phosphatidylinositol-4,5- bisphosphate (PI-4,5-P2) (Rameh et al., Nature 390(6656):192-196 (1997). In the cellular membrane, PI-4,5-P2 is also produced by another signaling pathway in which phosphatidylinositol 4-phosphate (PI4P) is phosphorylated by phosphatidylinositol 4- phosphate 5-kinases (PI4P5Ks).

[0003] Although the majority of PI-4,5-P2 is produced via the PI4P5K pathway, PI5P4Ks have been recognized as key regulators of many cell functions including metabolism, stress response, autophagy, and immunological processes (Hu et al., J. Lipid Res. 59:507-514 (2018); Lamia et al., Mol. Cell. Biol. 24(11):5080-5087 (2004); Shim et al., Proc. Natl. Acad. Sci. U. S. A. 113(27):7596-7601 (2016); Al-Ramahi et al., eLife 6:e29123 (2017); Lundquist et al., Mol. Cell 70(3):531-543 (2018); Bulley et al., Proc. Natl. Acad. Sci. U. S. A. 113(38):10571-10576 (2016); Keune et al., Adv. Biol. Regul. 53(2):179-189 (2013)). PIP4Ks have distinct catalytic and non-catalytic functions in controlling cellular metabolism and suppress PIP5K activity and insulin-stimulated production of PI(3,4,5)P3 (Wang et al., Cell Rep. 27:1991-2001 (2019)).

[0004] Dysregulation of the PI5P4K signaling pathway has been further linked to diseases such as diabetes, neurodegenerative disorders, and cancers (Lamia et al., Mol. Cell. Biol. 24(11): 5080-5087 (2004); Al-Ramahi et al., eLife 6:e29123 (2017); Jude et al., Oncogene 34(10):1253-1262 (2015); Luoh et al., Oncogene 23:1354-1363 (2004); Emerling et al., Cell 155(4):844-857 (2013). Analysis of PI(4,5)P2 levels in cells with single or double knockdown of PIP4K isoforms revealed an additive effect among all three isoforms that does not correlate with their relative catalytic activities. Double knockdown of the most active 1 ny-2730225220232001540 isoforms, PIP4KA / B, failed to phenocopy the triple knockdown, suggesting that catalytic activity is not the most important factor in regulating PI(4,5)P2 levels (Wang et al., Cell Rep. 27:1991-2001 (2019), and suggesting a unique role for PIP4KC.

[0005] These findings indicate that the inhibition of PI5P4K kinase activity and / or degradation of PI4P4K might have therapeutic potential across various diseases. SUMMARY OF THE INVENTION

[0006] In one aspect, provided is a compound of Formula (I’): ,or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q, V, R, Ring 1, Ring 3, and Ring 4 are as detailed herein.

[0007] In one aspect, provided is a compound of Formula (I):, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q, V, R, Ring 1, Ring 3, and Ring 4 are as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0008] In some embodiments of the compound of Formula (I), Q is Ring 5, which is as detailed herein. In some is a of Formula (II):(II), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein V, R, Ring 1, Ring 3, Ring 4, and Ring 5 are as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. 2 ny-2730225220232001540

[0009] In some embodiments of the compound of Formula (I), Q is RQ, which is as detailed herein. In some embodiments, provided is a compound of Formula (III): (III),or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein V, R, Ring 1, Ring 3, Ring 4, and RQare as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0010] In some embodiments of the compound of Formula (I), Q is of Formula (i), wherein Ring A, X, Ring B, W, Ring C, Linker, U, and Ring 2 are as detailed herein. In some embodiments, provided is a compound of Formula (IV):, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ring A, X, Ring B, W, Ring C, Linker, U, Ring 2, V, Ring 1, Ring 3, and Ring 4 are as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0011] In another aspect, provided is a pharmaceutical composition comprising a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I- b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I- s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, provided is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), 3 ny-2730225220232001540 (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV- e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In another aspect, provided is a pharmaceutical composition comprising a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I- u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, provided is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV- d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.

[0012] In another aspect, provided is a method of making a compound of Formula (I), (II), (III), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV- e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In another aspect, provided is a method of making a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I- n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV- c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0013] In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a compound of Formula (I), (II), (III), or (IV), or any 4 ny-2730225220232001540 related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I- b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I- s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C. In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C. 5 ny-2730225220232001540

[0014] In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a therapeutically effective amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV- e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C. In some embodiments, the methods are selective for PIP4K2C over PIP4K2A. In some embodiments, the methods are selective for PIP4K2C over PIP4K2B. In some embodiments, the methods are selective for PIP4K2C over both PIP4K2A and PIP4K2B. In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a therapeutically effective amount of the compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I- u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), 6 ny-2730225220232001540 (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C. In some embodiments, the methods are selective for PIP4K2C over PIP4K2A. In some embodiments, the methods are selective for PIP4K2C over PIP4K2B. In some embodiments, the methods are selective for PIP4K2C over both PIP4K2A and PIP4K2B.

[0015] In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to a subject in need thereof. In some embodiments, the method comprises reducing the level of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises degrading PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C.

[0016] In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a therapeutically effective amount of the compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV- h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to a subject in need thereof. In some 7 ny-2730225220232001540 embodiments, the method comprises reducing the level of PIP4K2C. In some embodiments, the method comprises degrading PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C.

[0017] In another aspect, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV- f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In another aspect, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV- e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.

[0018] In some embodiments, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a therapeutically effective 8 ny-2730225220232001540 amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or a (b) pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I- a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I- r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV- a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a therapeutically effective amount of the compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I- j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I- z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II- g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or a (b) pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.

[0019] In some aspects, the present invention is directed to methods of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4- phosphate 5-kinase (PIP5K) in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- 9 ny-2730225220232001540 p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I), (II), (III), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV- e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the scaffolding or interaction of PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5- kinase (PIP5K). In some aspects, the present invention is directed to methods of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5-kinase (PIP5K) in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I- m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV- b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), or any related formula such as Formula (I), (II), (III), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the scaffolding or interaction of PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5-kinase (PIP5K).

[0020] Any embodiments provided herein of a compound of formula (I) or (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, apply where applicable to any other 10 ny-2730225220232001540 formula detailed herein, the same as if each and every embodiment were specifically and individually listed. Thus, it is understood and described that each embodiment provided herein of a compound of formula (I) or (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, such as embodiments related to Ring 1, Ring 2, Ring 3, Ring 4, Ring 5, Ring A, Ring B, Ring C, R, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, RC, RD, RL, RQ, RV, Rw, Rx, Ry, Rz, Q, U, V, X, W, Linker, L1, L2, L3, and n apply to any one of formulae (i), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), the same as if each and every embodiment were specifically and individually listed. It is also understood and described that all such embodiments may be used in any of the pharmaceutical compositions, methods, kits, uses, etc. comprising such compounds or other aspects detailed herein.

[0021] As shown in working examples, compounds embraced by Formula (I’) and Formula (I) inhibit the activity or promote the degradation of at least one of PIP4K2A, PIP4K2B, and PIP4K2C. In some embodiments, compounds embraced by Formula (I’) and Formula (I) inhibit the activity or promote the degradation of PIP4K2C.

[0022] Without intending to be bound by any particular theory, the compounds of Formula (IV) and any related formula as applicable such as, e.g., (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), are believed to cause degradation of at least one of PIP4K2A, PIP4K2B, and PIP4K2C by recruitment of cells’ Ubiquitin / Proteasome System, whose function is to routinely identify and remove damaged proteins, into close proximity with PIP4K2A, PIP4K2B, or PIP4K2C as a result of binding between PIP4K2A, PIP4K2B, or PIP4K2C, and the targeting ligand. After destruction of a PIP4K2A, PIP4K2B, or PIP4K2C protein, the degrader is released and continues to be active. Thus, by engaging and exploiting the body’s own natural protein disposal system, the compounds of the present invention may represent a potential improvement over current small molecule inhibitors of PIP4K2A, PIP4K2B, and PIP4K2C and may overcome one or more limitations regarding their use. Therefore, effective intracellular concentrations of the degraders may be significantly lower than for small molecule PIP4K2A, PIP4K2B, or PIP4K2C inhibitors. Also, although PIP4K2A, PIP4K2B, and / or PIP4K2C genetic knockdown or knockout can be used to reduce the cellular concentration or amount of these proteins, it may 11 ny-2730225220232001540 be preferable to post-translationally disrupt, degrade, or destabilize PIP4K2A, PIP4K2B, and / or PIP4K2C proteins. Targeting proteins directly, rather than via the DNA or mRNA molecules that encode them, is a more direct and rapid method for reducing the scaffolding function of PIP4K proteins. Hence, degradation can allow some PIP4K2A, PIP4K2B, and / or PIP4K2C catalytic function to proceed while reducing the non-catalytic functions such as scaffolding between PIP4K2A, PIP4K2B, and / or PIP4K2C proteins and other cellular proteins and structures. Collectively, the present compounds may represent a set of new chemical tools for at least one of PIP4K2A, PIP4K2B, and PIP4K2C knockdown and may provide a potential treatment modality for PIP4K2A, PIP4K2B, and / or PIP4K2C-associated cancers and autophagy-dependent diseases (e.g., neurodegenerative disorders, insulin). In some instances, the present compounds may represent a set of new chemical tools for PIP4K2C knockdown and may provide a potential treatment modality for PIP4K2C- associated cancers and autophagy-dependent diseases (e.g., neurodegenerative disorders, insulin). The compounds may be used to enhance immune functions as described in, e.g., US20220168402A1 and Wang et al., Cell Rep. 27:1991-2001 (2019), each of which is incorporated herein by reference in its entirety. Inhibitors and degraders of PIP4K protein and methods for treating diseases or conditions by modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C are also disclosed in WO 2022 / 246025, herein incorporated by reference in its entirety. BRIEF DESCRIPTION OF THE FIGURES

[0023] Figure 1 shows modulation of phagocytosis by Compound U. The degradation of PIP4K2C by Compound U in human dendritic cells enhanced their phagocytosis of E. coli bioparticles, emphasizing the intrinsic immunological benefits of PIP4K2C targeting in myeloid cells.

[0024] Figure 2A shows the ability of Compound U to reduce tumor growth in the mouse syngeneic colorectal cancer model MC38-OVA. A marked reduction in tumor growth was observed in the treated group when compared to the vehicle control group. Figure 2B shows the survival of the mice treated with Compound U and mice treated with the vehicle control.

[0025] Figure 3 shows that degradation of PIP4K2C by Compound U enhances phagocytosis of E. coli bioparticles in human dendritic cells. The enhanced phagocytosis effect is not seen when using a PIP4K2C inhibitor compound that does not cause degradation, demonstrating the unique impact of a degrader of PIP4K2C over an inhibitory compound alone. 12 ny-2730225220232001540

[0026] Figure 4 shows that degradation of PIP4K2C by Compound U in dendritic cells leads to an increased uptake of dying tumor-derived material, adding to the enhanced engulfment of PIP4K2C-deficient tumor cells by immune cells.

[0027] Figure 5A shows that Compound U degrades endogenous PIP4K2C in vivo in rats. Figure 5B shows that Compound U degrades endogenous PIP4K2C in vivo in dogs. DETAILED DESCRIPTION Definitions

[0028] For use herein, unless clearly indicated otherwise, use of the terms “a”, “an” and the like refers to one or more.

[0029] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, “about X” includes and describes “X” per se.

[0030] “Alkyl” as used herein refers to and includes, unless otherwise stated, a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., C1-10means one to ten carbon atoms). Particular alkyl groups are those having 1 to 10 carbon atoms (a “C1-C10alkyl”), having 6 to 10 carbon atoms (a “C6-C10 alkyl”), having 1 to 6 carbon atoms (a “C1-C6 alkyl”), having 2 to 6 carbon atoms (a “C2-C6 alkyl”), or having 1 to 4 carbon atoms (a “C1-C4 alkyl”). Particular C1-C4alkyl groups include C1-C3alkyl groups. Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

[0031] “Alkylene” as used herein refers to the same residues as alkyl, but having bivalency. Particular alkylene groups are those having 1 to 10 carbon atoms (a “C1-C10 alkylene”), having 6 to 10 carbon atoms (a “C6-C10 alkylene”), having 1 to 6 carbon atoms (a “C1-C6 alkylene”), 1 to 5 carbon atoms (a “C1-C5alkylene”), 1 to 4 carbon atoms (a “C1-C4alkylene”) or 1 to 3 carbon atoms (a “C1-C3alkylene”). Examples of alkylene include, but are not limited to, groups such as methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), isopropylene (-CH2CH(CH3)-), butylene (-CH2(CH2)2CH2-), isobutylene (-CH2CH(CH3)CH2-), pentylene (-CH2(CH2)3CH2-), hexylene (-CH2(CH2)4CH2-), heptylene (-CH2(CH2)5CH2-), octylene (-CH2(CH2)6CH2-), and the like.

[0032] "Carbocyclyl” as used herein refers to and includes, unless otherwise stated, saturated and partially unsaturated hydrocarbon structures, having the number of carbon 13 ny-2730225220232001540 atoms designated (i.e., C3-C10 means three to ten carbon atoms). Cycloalkyl can consist of one ring (e.g., cyclohexyl), or multiple rings (e.g., adamantyl). In polycyclic ring systems, one or more of the fused rings can be carbocyclyl or aryl (e.g., spiro[4.5]decanyl, or 1,2,3,4- tetrahydronaphthalenyl), but excludes heterocyclyl or heteroaryl groups. A carbocyclyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof. Particular carbocyclyl groups are those having from 3 to 12 annular carbon atoms (a “C3-12carbocyclyl”), having 3 to 10 annular carbon atoms (a “C3-10carbocyclyl”), having 3 to 8 annular carbon atoms (a "C3-C8 carbocyclyl"), having 3 to 6 annular carbon atoms (a “C3-C6 carbocyclyl”), or having from 3 to 4 annular carbon atoms (a "C3-C4 carbocyclyl"). A carbocyclyl group having more than one ring where at least one ring is aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a carbocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at an aromatic ring position. In another variation, a carbocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at a non-aromatic ring position.

[0033] “Cycloalkyl” as used herein refers to and includes, unless otherwise stated, saturated cyclic hydrocarbon structures, having the number of carbon atoms designated (i.e., C3-C10means three to ten carbon atoms). Cycloalkyl can consist of one ring (e.g., cyclohexyl), or multiple rings (e.g., adamantyl). In polycyclic ring systems, one or more of the fused rings can be cycloalkyl or aryl (e.g., spiro[4.5]decanyl, or 1,2,3,4-tetrahydronaphthalenyl), but excludes heterocyclyl or heteroaryl groups. A cycloalkyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof. Particular cycloalkyl groups are those having from 3 to 12 annular carbon atoms (a “C3-12cycloalkyl”), having 3 to 10 annular carbon atoms (a “C3-10 cycloalkyl”), having 3 to 8 annular carbon atoms (a "C3-C8 cycloalkyl"), having 3 to 6 annular carbon atoms (a “C3-C6 cycloalkyl”), or having from 3 to 4 annular carbon atoms (a "C3-C4cycloalkyl"). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like. A cycloalkyl group having more than one ring where at least one ring is aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a cycloalkyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at an aromatic ring position. In another variation, a cycloalkyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at a non-aromatic ring position. 14 ny-2730225220232001540

[0034] “Aryl” or “Ar” as used herein refers to an unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings must be aromatic. Particular aryl groups are those having from 6 to 14 annular carbon atoms (a “C6-C14 aryl”).

[0035] “Heteroaryl” as used herein refers to an unsaturated aromatic cyclic group having from 1 to 14 annular carbon atoms and at least one annular heteroatom, including but not limited to heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl) which condensed rings must be aromatic. Particular heteroaryl groups are 5 to 14-membered rings having 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 5 to 10-membered rings having 1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 5, 6 or 7-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, particular heteroaryl groups are monocyclic aromatic 5-, 6- or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, particular heteroaryl groups are polycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. A heteroaryl group may be connected to the parent structure at a ring carbon atom or a ring heteroatom.

[0036] “Heterocycle”, “heterocyclic”, or “heterocyclyl” as used herein refers to a saturated or partially unsaturated non-aromatic cyclic group having a single ring or multiple condensed rings, and having from 1 to 14 annular carbon atoms and from 1 to 6 annular heteroatoms, such as nitrogen, sulfur or oxygen, and the like. A heterocycle comprising more than one ring may be fused, bridged or spiro, or any combination thereof. In fused ring systems, one or more of the fused rings can be cycloalkyl, aryl, or heteroaryl groups. The heterocyclyl group may be optionally substituted independently with one or more substituents described herein. Particular heterocyclyl groups are 3 to 14-membered rings having 1 to 13 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 12-membered rings having 1 to 11 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 10-membered rings having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 8-membered rings having 1 to 7 annular 15 ny-2730225220232001540 carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 3 to 6-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, heterocyclyl includes monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annular carbon atoms and 1 to 2, 1 to 3, or 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, heterocyclyl includes polycyclic non-aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. A heterocyclyl group having more than one ring where at least one ring is aromatic may be connected to the parent structure at either an aromatic ring position or at a non- aromatic ring position. In one variation, a heterocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at an aromatic ring position. In another variation, a heterocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at a non-aromatic ring position.

[0037] “Halo” or “halogen” refers to elements of the Group 7 of the periodic table. Preferred halo groups include fluorine, chlorine, bromine and iodine. Where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be but are not necessarily the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. An alkyl group in which each hydrogen is replaced with a halo group is referred to as a “perhaloalkyl.” A preferred perhaloalkyl group is trifluoromethyl (-CF3). Similarly, “perhaloalkoxy” refers to an alkoxy group in which a halogen takes the place of each H in the hydrocarbon making up the alkyl moiety of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (–OCF3).

[0038] “Carbonyl” refers to the group C=O.

[0039] “Oxo” refers to the moiety =O.

[0040] “Optionally substituted” unless otherwise specified means that a group may be unsubstituted or substituted with one or more (e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group in which the substituents may be the same of different. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In another embodiment, an optionally substituted group has four 16 ny-2730225220232001540 substituents. In some embodiments, an optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents. In one embodiment, an optionally substituted group is unsubstituted.

[0041] It is understood that aspects and embodiments described herein as “comprising” include “consisting of” and “consisting essentially of” embodiments.

[0042] The term “pharmaceutically acceptable salt”, as used herein, of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. See, e.g., Handbook of Pharmaceutical Salts Properties, Selection, and Use, International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), which is incorporated herein by reference. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, trifluoroacetic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N- ethylpiperidine, and the like. 17 ny-2730225220232001540

[0043] Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with one another. By way of illustration, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds of this disclosure are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, for example, amide-containing compounds are understood to include their imidic acid tautomers. Likewise, imidic-acid containing compounds are understood to include their amide tautomers.

[0044] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- (or as (D)- or (L)- for amino acids). The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using conventional techniques, for example, chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or the resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC), and chiral supercritical fluid chromatography (SFC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless specified otherwise, it is intended that the present disclosure includes both E and Z geometric isomers. Likewise, cis- and trans- are used in their conventional sense to describe relative spatial relationships.

[0045] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds, but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers, or mixtures thereof (e.g., racemic mixtures), and includes “enantiomers,” which refers to two stereoisomers whose structures are non-superimposable mirror images of one another. “Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other. Where enantiomeric and / or diastereomeric forms exist of a given structure, flat bonds indicate that all stereoisomeric forms of the depicted structure may 18 ny-2730225220232001540 be present, enantiomeric and / or diastereomeric forms existwedged or hashed bonds without “R”, “S”, or “abs” indicate the composition is made up of at least 90% by weight of a mixture of isomers with known relative stereochemistry,enantiomeric and / or diastereomeric forms exist of a given structure, wedged or hashed bonds with “R”, “S”, or “abs” indicate the composition is made up of at least 90% by weight of a single enantiomer or diastereomer with known absolute stereochemistry, e.g.,.

[0046] In some instances, diastereomeric mixtures are designated using “r” and / or “s” configurations. In such instances, relative stereochemistry is designated by lowercase (“r” or “s”), and absolute stereochemistry is designated by uppercase (“R” or “S”).

[0047] The term “disease” as used herein is regarded as a state of health of a subject, wherein the subject cannot maintain homeostasis, and / or wherein, if the disease is not ameliorated, then the subject's health further deteriorates. In contrast, a "disorder" in a subject is a state of health in which the subject is able to maintain homeostasis, but the subject’s health is less favorable than it in the absence of the disorder. A disorder does not necessarily cause a further decrease in the subject’s health, when left untreated.

[0048] The term “subject” (or “patient”) as used herein includes mammals prone to or suffering from the indicated disease or disorder e.g., a human or a non-human mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a companion animal such as dogs and cats; in some embodiments, the subject is a livestock animal such as cows, horses, sheep, goats, and pigs; in some embodiments, the subject may be other domesticated and wild animals. A subject “in need of” treatment according to the present 19 ny-2730225220232001540 invention may be “suffering from or suspected of suffering from” a specific disease or disorder; may have been positively diagnosed with the disease or disorder; or otherwise presents with a sufficient number of risk factors or combination of symptoms such that a medical professional could diagnose the subject with the disease or disorder or suspect that the subject was suffering from the disease or disorder.

[0049] As used herein, the term, "therapeutically effective amount" is an amount of a compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or a composition including a compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is effective in yielding the desired therapeutic response in a particular subject in need thereof. Therefore, the term "therapeutically effective amount" includes the amount of a compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, that when administered, induces an improvement in the disease or disorder to be treated, or is sufficient to prevent or slow development or progression of the disease or disorder, or alleviate to some extent one or more of the symptoms of the disease or disorder being treated in a subject, or kills or inhibits the growth of diseased cells (e.g., cancer cells, or autophagy-dependent disease cells), or reduces the amount of at least one of PIP4K2A, PIP4K2B, and PIP4K2C (e.g., reduces the amount of at least PIP4K2C) in diseased cells.

[0050] As used herein, the term “neurodegenerative diseases and disorders” refers to conditions characterized by progressive degeneration and / or death of nerve cells, including problems with movement or mental functioning. Representative examples include Alzheimer’s disease (AD) and related dementias, Parkinson’s disease (PD) and related dementias, prion disease, motor neuron diseases (MND), Huntington’s disease (HD), Pick’s syndrome, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), primary progressive aphasia (PPA), amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), multiple sclerosis (MS), and other dementias (e.g., vascular dementia (VaD), Lewy body dementia (LBD), semantic dementia, and frontotemporal lobar dementia (FTD)).

[0051] As used herein, the term “autoimmune disease” refers to conditions where the immune system produces antibodies that attack normal body tissues. Representative examples of autoimmune diseases include, without limitation, autoimmune hematological disorders (e.g., hemolytic anemia, aplastic anemia, anhidrotic ectodermal dysplasia, pure red cell anemia and idiopathic thrombocytopenia), Sjogren’s syndrome, Hashimoto thyroiditis, rheumatoid arthritis, juvenile (type 1) diabetes, polymyositis, scleroderma, Addison’s disease, 20 ny-2730225220232001540 lupus including systemic lupus erythematosus, vitiligo, pernicious anemia, glomerulonephritis, pulmonary fibrosis, celiac disease, polymyalgia rheumatica, multiple sclerosis, ankylosing spondylitis, alopecia areata, vasculitis, autoimmune uveoretinitis, lichen planus, bullous pemphigus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, myasthenia gravis, immunoglobulin A nephropathy, Wegener granulomatosis, autoimmune oophoritis, sarcoidosis, rheumatic carditis, ankylosing spondylitis, Grave’s disease, autoimmune thrombocytopenic purpura, psoriasis, psoriatic arthritis, dermatitis herpetiformis, ulcerative colitis, and temporal arteritis, and the like.

[0052] As used herein, the term “cell proliferative disease or disorder” refers to a condition characterized by dysregulated or abnormal cell growth, or both, including noncancerous conditions such as neoplasms, precancerous conditions, benign tumors, and cancer.

[0053] As used herein, “cell proliferative diseases or disorders of the hematological system” include lymphoma, leukemia, myeloid neoplasms, mast cell neoplasms, myelodysplasia, benign monoclonal gammopathy, lymphomatoid papulosis, polycythemia vera, chronic myelocytic leukemia, agnogenic myeloid metaplasia, and essential thrombocythemia. Representative examples of hematologic cancers may thus include multiple myeloma, lymphoma (including T-cell lymphoma, Hodgkin’s lymphoma, non- Hodgkin’s lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and ALK+ anaplastic large cell lymphoma (e.g., B-cell non- Hodgkin’s lymphoma selected from diffuse large B-cell lymphoma (e.g., germinal center B- cell-like diffuse large B-cell lymphoma or activated B-cell-like diffuse large B-cell lymphoma), Burkitt’s lymphoma / leukemia, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia, metastatic pancreatic adenocarcinoma, refractory B-cell non-Hodgkin’s lymphoma, and relapsed B-cell non-Hodgkin’s lymphoma, childhood lymphomas, and lymphomas of lymphocytic and cutaneous origin, e.g., small lymphocytic lymphoma, leukemia, including childhood leukemia, hairy-cell leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloid leukemia (e.g., acute monocytic leukemia), chronic lymphocytic leukemia, small lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, and mast cell leukemia, myeloid neoplasms and mast cell neoplasms.

[0054] As used herein, “cell proliferative diseases or disorders of the liver” include all forms of cell proliferative disorders affecting the liver. Cell proliferative disorders of the liver 21 ny-2730225220232001540 may include liver cancer (e.g., hepatocellular carcinoma, intrahepatic cholangiocarcinoma and hepatoblastoma), a precancer or precancerous condition of the liver, benign growths or lesions of the liver, and malignant growths or lesions of the liver, and metastatic lesions in tissue and organs in the body other than the liver. Cell proliferative disorders of the liver may include hyperplasia, metaplasia, and dysplasia of the liver.

[0055] As used herein, “cell proliferative diseases or disorders of the brain” include all forms of cell proliferative disorders affecting the brain. Cell proliferative disorders of the brain may include brain cancer (e.g., gliomas, glioblastomas, meningiomas, pituitary adenomas, vestibular schwannomas, and primitive neuroectodermal tumors (medulloblastomas)), a precancer or precancerous condition of the brain, benign growths or lesions of the brain, and malignant growths or lesions of the brain, and metastatic lesions in tissue and organs in the body other than the brain. Cell proliferative disorders of the brain may include hyperplasia, metaplasia, and dysplasia of the brain.

[0056] As used herein, “cell proliferative diseases or disorders of the lung” include all forms of cell proliferative disorders affecting lung cells. Cell proliferative disorders of the lung include lung cancer, precancer and precancerous conditions of the lung, benign growths or lesions of the lung, hyperplasia, metaplasia, and dysplasia of the lung, and metastatic lesions in the tissue and organs in the body other than the lung. Lung cancer includes all forms of cancer of the lung, e.g., malignant lung neoplasms, carcinoma in situ¸ typical carcinoid tumors, and atypical carcinoid tumors. Lung cancer includes small cell lung cancer (“SLCL”), non-small cell lung cancer (“NSCLC”), adenocarcinoma, small cell carcinoma, large cell carcinoma, squamous cell carcinoma, and mesothelioma. Lung cancer can include “scar carcinoma”, bronchoalveolar carcinoma, giant cell carcinoma, spindle cell carcinoma, and large cell neuroendocrine carcinoma. Lung cancer also includes lung neoplasms having histologic and ultrastructural heterogeneity (e.g., mixed cell types). In some embodiments, a compound treats non-metastatic or metastatic lung cancer (e.g., NSCLC, ALK-positive NSCLC, NSCLC harboring ROS1 rearrangement, lung adenocarcinoma, and squamous cell lung carcinoma).

[0057] As used herein, “cell proliferative diseases or disorders of the colon” include all forms of cell proliferative disorders affecting colon cells, including colon cancer, a precancer or precancerous conditions of the colon, adenomatous polyps of the colon and metachronous lesions of the colon. Colon cancer includes sporadic and hereditary colon cancer, malignant colon neoplasms, carcinoma in situ, typical carcinoid tumors, and atypical carcinoid tumors, 22 ny-2730225220232001540 adenocarcinoma, squamous cell carcinoma, and squamous cell carcinoma. Colon cancer can be associated with a hereditary syndrome such as hereditary nonpolyposis colorectal cancer, familiar adenomatous polyposis, MYH associated polyposis, Gardner’s syndrome, Peutz- Jeghers syndrome, Turcot’s syndrome and juvenile polyposis. Cell proliferative disorders of the colon may also be characterized by hyperplasia, metaplasia, or dysplasia of the colon.

[0058] As used herein, “cell proliferative diseases or disorders of the pancreas” include all forms of cell proliferative disorders affecting pancreatic cells. Cell proliferative disorders of the pancreas may include pancreatic cancer, a precancer or precancerous condition of the pancreas, hyperplasia of the pancreas, dysplasia of the pancreas, benign growths or lesions of the pancreas, and malignant growths or lesions of the pancreas, and metastatic lesions in tissue and organs in the body other than the pancreas. Pancreatic cancer includes all forms of cancer of the pancreas, including ductal adenocarcinoma, adenosquamous carcinoma, pleomorphic giant cell carcinoma, mucinous adenocarcinoma, osteoclast-like giant cell carcinoma, mucinous cystadenocarcinoma, acinar carcinoma, unclassified large cell carcinoma, small cell carcinoma, pancreatoblastoma, papillary neoplasm, mucinous cystadenoma, papillary cystic neoplasm, and serous cystadenoma, and pancreatic neoplasms having histologic and ultrastructural heterogeneity (e.g., mixed cell).

[0059] As used herein, “cell proliferative diseases or disorders of the prostate” include all forms of cell proliferative disorders affecting the prostate. Cell proliferative disorders of the prostate may include prostate cancer, a precancer or precancerous condition of the prostate, benign growths or lesions of the prostate, and malignant growths or lesions of the prostate, and metastatic lesions in tissue and organs in the body other than the prostate. Cell proliferative disorders of the prostate may include hyperplasia, metaplasia, and dysplasia of the prostate.

[0060] As used herein, “cell proliferative diseases or disorders of the ovary” include all forms of cell proliferative disorders affecting cells of the ovary. Cell proliferative disorders of the ovary may include a precancer or precancerous condition of the ovary, benign growths or lesions of the ovary, ovarian cancer, and metastatic lesions in tissue and organs in the body other than the ovary. Cell proliferative disorders of the ovary may include hyperplasia, metaplasia, and dysplasia of the ovary.

[0061] As used herein, “cell proliferative diseases or disorders of the breast” include all forms of cell proliferative disorders affecting breast cells. Cell proliferative disorders of the breast may include breast cancer, a precancer or precancerous condition of the breast, benign 23 ny-2730225220232001540 growths or lesions of the breast, and metastatic lesions in tissue and organs in the body other than the breast. Cell proliferative disorders of the breast may include hyperplasia, metaplasia, and dysplasia of the breast.

[0062] As used herein, “cell proliferative diseases or disorders of the skin” include all forms of cell proliferative disorders affecting skin cells. Cell proliferative disorders of the skin may include a precancer or precancerous condition of the skin, benign growths or lesions of the skin, melanoma, malignant melanoma or other malignant growths or lesions of the skin, and metastatic lesions in tissue and organs in the body other than the skin. Cell proliferative disorders of the skin may include hyperplasia, metaplasia, and dysplasia of the skin.

[0063] As used herein, “cell proliferative diseases or disorders of the endometrium” include all forms of cell proliferative disorders affecting cells of the endometrium. Cell proliferative disorders of the endometrium may include a precancer or precancerous condition of the endometrium, benign growths or lesions of the endometrium, endometrial cancer, and metastatic lesions in tissue and organs in the body other than the endometrium. Cell proliferative disorders of the endometrium may include hyperplasia, metaplasia, and dysplasia of the endometrium.

[0064] In some embodiments, the cancer is a hematological cancer e.g., leukemia, lymphoma or multiple myeloma. Compounds of Formula (I’) or (I)

[0065] In one aspect, provided is a compound of Formula (I’), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; 24 ny-2730225220232001540 Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; V is a bond, -C1-4alkylene-, -C(O)-, -C(O)O-#, -OC(O)# -C1-4alkylene-C(O)-#, - C(O)N(RV)-#, -N(RV)C(O)-#, -OC(O)N(RV)-#, -N(RV)-C(O)O#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Ring 5, wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b; or Q is of Formula (i)wherein:Ring A is selected from the group consisting of , ,, , of which is optionally substituted with one or more C1-4alkyl or halo; X is a bond, -O-, -NH-, or -NHC(O)-; 25 ny-2730225220232001540 ofwhich is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, -O-, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and L3is C1-10alkylene, C1-10alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1-10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; 26 ny-2730225220232001540 each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1- 4hydroxyalkyl, or C1-4aminoalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide or carbamate; and wherein: 27 ny-2730225220232001540 when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; and wherein: when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is -OC(O)#, then RQis not tert-butyl.

[0066] In one aspect, provided is a compound of Formula (I’) ,or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; V is a bond, -C1-4alkylene-, -C(O)-, -C(O)O-#, -OC(O)# -C1-4alkylene-C(O)-#, - C(O)N(RV)-#, -N(RV)C(O)-#, -OC(O)N(RV)-#, -N(RV)-C(O)O#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Ring 5, wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b; or Q is of Formula (i) 28 ny-2730225220232001540 wherein:Ring A is selected from the group consisting of ,each of which is optionally substituted with one or moreC1-4alkyl or halo; X is a bond, -O-, -NH-, or -NHC(O)-;of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, -O-, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6 alkylene; 29 ny-2730225220232001540 L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and L3is C1-10alkylene, C1-10alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1-10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1- 4hydroxyalkyl, or C1-4aminoalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; 30 ny-2730225220232001540 each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide or carbamate; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0067] In one aspect, provided is a compound of Formula (I):, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1, wherein each 4- to 8-membered heterocyclyl of Ring 1 comprises at least one heteroatom selected from N and O; 31 ny-2730225220232001540 V is a bond, -C1-4alkylene-, -C(O)-, -C1-4alkylene-C(O)-#, -C(O)N(RV)-#, - N(RV)C(O)-#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Ring 5, wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b, or Q is of Formula (i)wherein: Ring A is selected from the group consisting of,of which is optionally substituted with one or more C1-4alkyl or halo; X is a bond, -O-, -NH-, or -NHC(O)-;, , , , and , each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; 32 ny-2730225220232001540 Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and L3is C1-10alkylene, C1-10alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1-10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; 33 ny-2730225220232001540 each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n- C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide, or (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; and wherein: when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is -OC(O)#, then RQis not tert-butyl.

[0068] In one aspect, provided is a compound of Formula (I):, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; 34 ny-2730225220232001540 Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1, wherein each 4- to 8-membered heterocyclyl of Ring 1 comprises at least one heteroatom selected from N and O; V is a bond, -C1-4alkylene-, -C(O)-, -C1-4alkylene-C(O)-#, -C(O)N(RV)-#, - N(RV)C(O)-#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Ring 5, wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b, or Q is of Formula (i)wherein:Ring A is selected from the group consisting of , ,, , one or more C1-4alkyl or halo; X is a bond, -O-, -NH-, or -NHC(O)-; 35 ny-2730225220232001540 ofwhich is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and L3is C1-10alkylene, C1-10alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1-10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; 36 ny-2730225220232001540 each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n- C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide, or (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0069] In one aspect, provided is a compound of Formula (I): 37 ny-2730225220232001540 , or a tautomer orsalt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl, saturated 4- to 8-membered heterocyclyl comprising at least one annular ether or annular amine, or saturated 4- to 8-membered heterocyclyl comprising an annular amide, each of which is optionally substituted with one or more R1; V is a bond, -C1-4alkylene-, -C(O)-, -C1-4alkylene-C(O)-#, -C(O)N(RV)-#, - N(RV)C(O)-#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Ring 5, wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5bor Q is of, (i) wherein: 38 ny-2730225220232001540 Ring A is selected from the group consisting of ,of which is optionally substituted with one or moreor X is a bond, -O-, -NH-, or -NHC(O)-;of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and 39 ny-2730225220232001540 L3is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1- 10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n- C1-4alkyl; and each n is independently 0, 1, or 2; wherein: 40 ny-2730225220232001540 (i) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is -C(O)- or -C1-4alkylene-C(O)-#; and (ii) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amide, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is a bond or -C1-4alkylene-; and (iii) when Ring 1 is C4-8cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then: (a) V is -C(O)N(RV)-#, -N(RV)C(O)-#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#; or (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5; or (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0070] In one aspect, provided is a compound of Formula (I):, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; 41 ny-2730225220232001540 Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1, wherein each 4- to 8-membered heterocyclyl of Ring 1 comprises at least one N heteroatom; V is a -C(O)-, -C1-4alkylene-C(O)-#, -C(O)N(RV)-#, -N(RV)C(O)-#, or -C1-4alkylene- C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Q is of Formula (i)wherein: Ring A is, is optionally substituted with one or more C1-4alkyl or halo; X is a bond, or -NH-; Ring B is selected from the group consisting, and, of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond or -O-; Ring C is optional, and when present is 6-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, C1-10alkylene, or C(O)C1-10alkylene; U is absent when Ring 2 is absent, and is a bond when Ring 2 is present; Ring 2 is optional, and when present is 6-membered or 11-membered heterocyclyl optionally substituted with one or more R2a; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; 42 ny-2730225220232001540 each R2a, R3a, and R4ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R3band R4bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n- C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (i) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is -C(O)- or -C1-4alkylene-C(O)-#; and (ii) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at an annular amide, optionally substituted with one or more R1, then V is attached to the annular amide nitrogen atom of Ring 1 and is a bond or -C1-4alkylene-; and (iii) when Ring 1 is C4-8 cycloalkyl, optionally substituted with one or more R1, then: (a) V is -C(O)N(RV)-# or -N(RV)C(O)-#; or (b) Ring 2 is 6- or 11-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0071] In some embodiments of the compound of Formula (I), R is chloro, fluoro, or bromo. In some embodiments of the compound of Formula (I), R is chloro or fluoro. In some 43 ny-2730225220232001540 embodiments of the compound of Formula (I), R is chloro. In some embodiments of the compound of Formula (I), R is fluoro.

[0072] In some embodiments of the compound of Formula (I), Ring 1 is a C4-8cycloalkyl optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1. In some embodiments, Ring, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 is or.. some embodiments, Ring 1 is .

[0073] In some embodiments, Ring 1 is. Ring 1. .

[0074] In some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8- membered heterocyclyl comprising at least one annular ether or annular amine, optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8-membered heterocyclyl comprising at least one annular ether or annular amine, optionally substituted with one or more R1. In some embodiments of the compound of Formula (I), Ring 1 is a 44 ny-2730225220232001540 saturated 6- to 8-membered heterocyclyl comprising at least one annular ether or annular amine, optionally substituted with one or more R1. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 is , wherein # indicatesattachment to V, each of which is optionally one or more R1. In some embodiments, Ring 1 is, wherein # indicates attachment to V, each of which is optionally substituted with one or more R1. In some

[0075] In some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8- membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments, Ring 1 is, optionally substituted with one or more R1, wherein # indicates attachment to V.In some embodiments, Ring 1 is or , optionallysubstituted with one embodiments, Ring 1 is . In someembodiments, Ring 1 is . 45 ny-2730225220232001540

[0076] In some embodiments of the compound of Formula (I), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is - C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)- ##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is a C5-8cycloalkyl optionally substituted with one or more R1, and V is -C(O)N(RV)-##, -N(RV)C(O)- ##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a C6-8cycloalkyl optionally substituted with one or more R1, and V is -C(O)N(RV)- ##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, and V is -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene- C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1orof which is optionally substituted with one or more R1, and V is - C(O)N(RV)-##, -N(RV)C(O)-##, - ##. In some embodiments, Ringis optionally substituted with one or more R1, and V is -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-N - some4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. 46 ny-2730225220232001540

[0077] In some embodiments of the compound of Formula (I), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is - OC(O)N(RV)-##, -N(RV)-C(O)O##, -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene- C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, and V is -OC(O)N(RV)-##, -N(RV)-C(O)O##, -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, and V is -OC(O)N(RV)-##, - N(RV)-C(O)O##, -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, and V is -OC(O)N(RV)-##, - Nor C ,or N C -##. In some embodiments, Ring 1 is , and V is -OC(O)N(RV)-##, -N(RV)- C(O)O##, -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene- 47 ny-2730225220232001540 N N -OC(O)N(RV)-##, -N(RV)-C(O)O##, -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene- C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##.

[0078] In some embodiments of the compound of Formula (I), Ring 1 is a 4- to 8- membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene- N(RV)C(O)-##. In some embodiments, Ring 1 is a 5- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene- N(RV)C(O)-##. In some embodiments, Ring 1 is a 6- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene- N(RV)C(O)-##.

[0079] In some embodiments of the compound of Formula (I), Ring 1 is a 4- to 8- membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is -OC(O)N(RV)-##, -N(RV)-C(O)O##, -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene- C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a 5- to 8- 48 ny-2730225220232001540 membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is -OC(O)N(RV)-##, -N(RV)-C(O)O##, -C(O)N(RV)- ##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a 6- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is -OC(O)N(RV)-##, - N(RV)-C(O)O##, -C(O)N(RV)-##, -N(RV)C(O)-##, -C1-4alkylene-C(O)N(RV)-## or -C1-4alkylene-N(RV)C(O)-##.

[0080] In some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8- membered heterocyclyl comprising at least one annular amine and no annular amide, optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is -C(O)-## or -C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is - C(O)-## or -C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 6- to 8-membered heterocyclyl comprising at least one or annular amine, optionally substituted with one or more R1, and V is -C(O)-## or -C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1, and V is -C(O)-## or -C1-4alkylene- C -##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 isor , each of which is optionally substituted with one or more R1, wherein # indicates - - - 4alkylene-C(O)-##. In someembodiments, Ring 1 is , , or , each of which is optionally substituted with oneembodiments, Ring 1 is , and V is -C(O)-## or -C1-4alkylene-C(O). In some 49 ny-2730225220232001540 embodiments, Ring 1 someembodiments, Ring 1 .

[0081] In some , a 4- to 8- membered heterocyclyl comprising at least one annular amine and no annular amide, optionally substituted with one or more R1, wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is -C(O)O-##, -OC(O)##, -C(O)-## or -C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8- membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is -C(O)O-##, -OC(O)##, -C(O)-## or -C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 6- to 8-membered heterocyclyl comprising at least one or annular amine, optionally substituted with one or more R1, and V is -C(O)O-##, -OC(O)##, -C(O)-## or -C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1, and V is -C(O)O-##, -OC(O)##, -C(O)-## or -C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments,or , each of which is optionally substituted with one or more R1, wherein # indicates attachment to V; and V is -OC(O)##, -C - - 4alkylene-C(O)-##. In some embodiments, Ring 1is , , or , each of which is optionally substituted with one or moreRing 1 is , and V is -OC(O)##, -C(O)-## or -C1-4alkylene-C(O). In some 50 ny-2730225220232001540 embodiments, Ring 1 Insome embodiments, Ring 1C(O).

[0082] In some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8- membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, and V is a bond or -C1-4alkylene-. In some embodiments, Ring 1, optionally substituted with one or more R1, wherein # indicates attachment to V; and V is a bond or -C1-4alkylene-. In some embodiments, Ring 1 is, each of which is optionally substituted with one or more R1; and V is a bond or -C1-4alkylene-. In some embodiments, Ring 1 is, and V is a bond or -C1-4alkylene-. In some embodiments, Ring 1 is, and V is a bond or -C1-4alkylene-.

[0083] In some embodiments, Ring 1 comprises an intraannular amide, or V comprises an amide, or V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide. In some embodiments, Ring 1 comprises an intraannular amide. In some embodiments, V comprises an amide. In some embodiments, V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide. In some embodiments of Formula (I), (II), (III), or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 1 to which it is attached, to form an amide. In some embodiments of Formula (I) or (II), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form an amide. In some embodiments of Formula (I) or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form an amide.

[0084] In some embodiments, V comprises a carbamate, or V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form a carbamate. In some 51 ny-2730225220232001540 embodiments, V comprises a carbamate. In some embodiments, V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form a carbamate. In some embodiments of Formula (I’), (I), (II), (III), or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 1 to which it is attached, to form a carbamate. In some embodiments of Formula (I’), (I), or (II), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form a carbamate. In some embodiments of Formula (I’), (I), or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form a carbamate.

[0085] In some embodiments, when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is -C(O)- or -C1-4alkylene-C(O)-#.

[0086] In some embodiments, when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is -OC(O)##.

[0087] In some embodiments, when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amide, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is a bond or -C1-4alkylene-.

[0088] In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then (a) V is -C(O)N(RV)-#, -N(RV)C(O)-#, -C1-4alkylene- C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#; or (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5; or (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2.

[0089] In some embodiments, when Ring 1 is C4-8cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then (a) V is -OC(O)N(RV)-# or -N(RV)-C(O)O#, wherein # indicates attachment to Ring 1; or (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is -C(O)O-# and is attached to an annular nitrogen atom of Ring 5, wherein # indicates attachment to Ring 1; or (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)O-# and is attached to an annular nitrogen atom of Ring 2, wherein # indicates attachment to Ring 1. 52 ny-2730225220232001540

[0090] In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then V is -C(O)N(RV)-#, -N(RV)C(O)-#, -C1-4alkylene- C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#.

[0091] In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then V is -OC(O)N(RV)-# or -N(RV)-C(O)O#, wherein # indicates attachment to Ring 1.

[0092] In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5.

[0093] In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is -C(O)O-# and is attached to an annular nitrogen atom of Ring 5, wherein # indicates attachment to Ring 1.

[0094] In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2.

[0095] In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)O-# and is attached to an annular nitrogen atom of Ring 2, wherein # indicates attachment to Ring 1.

[0096] In some embodiments of the compound of Formula (I), the compound is of Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w): 53 ny-2730225220232001540(I-n) (I-o) 54 ny-2730225220232001540wherein Q, R, Ring 3, and Ring 4 are as defined herein for Formula (I). In some embodiments, Ring 4 is present.

[0097] In some embodiments of the compound of Formula (I), the compound is of Formula (I-z), , , , , , , :(I-ab) (I-ac) 55 ny-2730225220232001540(I-af) (I-ag) wherein Q, R, Ring 3, and Ring 4 are as defined herein for Formula (I). In some embodiments, Ring 4 is present.

[0098] In some embodiments of the compound of Formula (I), or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is phenyl optionally substituted with one or more R3b, and Ring 4 is phenyl optionally substituted with one or more R4b. In some embodiments, the compound is of Formula, , a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein each m is independently an integer from 0 to 4, and Q, V, R, and Ring 1 are as described herein for Formula (I). In some embodiments, each m is independently an integer from 0 to 2. In some embodiments, each m is 0 or 1. In some embodiments, Ring 3 is Formula (I-y)(I-y), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q, V, R, and Ring 1 are as described herein for Formula (I). In some embodiments of Formula (I-x) or (I-y), Ring 1 is cyclohexyl or piperidinyl, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 is cyclohexyl or piperidinyl, each of which is optionally 56 ny-2730225220232001540 substituted with one or more R1, and Q is of Formula (i). In some embodiments, Ring 1 is cyclohexyl or piperidinyl, each of which is optionally substituted with one or more R1, and Q is RQ.

[0099] In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is present. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is not cycloalkyl or tetrahydropyranyl. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is phenyl optionally substituted with one or more R4b, 5- to 6-membered heteroaryl optionally substituted with one or more R4b, or 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, wherein Ring 4 is not tetrahydropyranyl. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is phenyl optionally substituted with one or more R4bor 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, wherein Ring 4 is not tetrahydropyranyl.

[0100] In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is 5- or 6-membered heterocyclyl optionally substituted with one or more R3aand Ring 4 is phenyl optionally substituted with one or more R4b.

[0101] In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is 5- or 6-membered heterocyclyl optionally substituted with one or more R3aand Ring 4 is 5- or 6-membered heteroaryl optionally substituted with one or more R4b.

[0102] In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is phenyl optionally substituted with one or more R3b, and Ring 4 is 5- or 6-membered heterocyclyl optionally substituted with one or more R4a.

[0103] In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is phenyl optionally substituted with one or more R3b, and Ring 4 is 3- to 6-membered cycloalkyl optionally substituted with one or more R4a.

[0104] In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), 57 ny-2730225220232001540 (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is 5- or 6-membered heteroaryl optionally substituted with one or more R3b, and Ring 4 is phenyl optionally substituted with one or more R4b.

[0105] In some embodiments of the compound of Formula (I), or related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), and (I-y), Q is H.

[0106] In some embodiments of the compound of Formula (I), or related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), and (I-y), Q is RQ. In some embodiments, RQis H, halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, RQis halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, RQis C1-4alkyl or C1-4haloalkyl. In some embodiments, RQis C1-2alkyl or C1-2haloalkyl. In some embodiments, RQis methyl. In some embodiments, RQis H.

[0107] In some embodiments of the compound of Formula (I), Q is Ring 5, and the compound is of Formula (II), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ring 5, V, Ring 1, R, Ring 3, and Ring 4 are as described for Formula (I). In some embodiments, Ring 4 is present.

[0108] In some embodiments of the compound of Formula (I), Q is Ring 5, and the compound is of Formula, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally 58 ny-2730225220232001540 substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; V is a bond, -C1-4alkylene-, -C(O)-, -C(O)O-#, -OC(O)# -C1-4alkylene-C(O)-#, - C(O)N(RV)-#, -N(RV)C(O)-#, -OC(O)N(RV)-#, -N(RV)-C(O)O#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; 59 ny-2730225220232001540 each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1 or Ring 5 to which it is attached, to form an amide or carbamate; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0109] In some embodiments of the compound of Formula (I), Q is RQ, and the compound is of Formula (III), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; 60 ny-2730225220232001540 V is a bond, -C1-4alkylene-, -C(O)-, -C(O)O-#, -OC(O)# -C1-4alkylene-C(O)-#, - C(O)N(RV)-#, -N(RV)C(O)-#, -OC(O)N(RV)-#, -N(RV)-C(O)O#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1 to which it is attached, to form an amide or carbamate; and wherein: 61 ny-2730225220232001540 when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; and wherein: when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, and V is -OC(O)#, then RQis not tert-butyl.

[0110] In some embodiments of the compound of Formula (I), Q is RQ, and the compound is of Formula (III) ,or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; V is a bond, -C1-4alkylene-, -C(O)-, -C(O)O-#, -OC(O)# -C1-4alkylene-C(O)-#, - C(O)N(RV)-#, -N(RV)C(O)-#, -OC(O)N(RV)-#, -N(RV)-C(O)O#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, 62 ny-2730225220232001540 N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1 to which it is attached, to form an amide or carbamate; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0111] In some embodiments of the compound of Formula (I) or (II), Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b; wherein each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; and 63 ny-2730225220232001540 each R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene- S(O)nRx.

[0112] In some embodiments of the compound of Formula (I) or (II), Ring 5 is C3-10 cycloalkyl optionally substituted with one or more R5a, wherein each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 5 is C5-10cycloalkyl optionally substituted with one or more R5a, wherein each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 5 is C5-6 cycloalkyl optionally substituted with one or more R5a, wherein each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 5 is C6 cycloalkyl optionally substituted with one or more R5a, wherein each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo.

[0113] In some embodiments of the compound of Formula (I) or (II), Ring 5 is 4- to 12- membered heterocyclyl optionally substituted with one or more R5a, wherein each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 5 is 5- to 6-membered heterocyclyl optionally substituted with one or more R5a. In some embodiments, Ring 5 is piperidinyl or piperazinyl, each of which is optionally substituted with one or more R5a. In some embodiments, Ring 5 is 10- to 12- membered heterocyclyl optionally substituted with one or more R5a. In some embodiments, 64 ny-2730225220232001540 Ring 5 , each of which is optionallyto V. In some embodiments, Ring 5 , each of whichis optionally substituted with one or more wherein # indicates attachment to V. In some embodiments, Ring 5 is , each of which is optionallysubstituted with one or more R5a, wherein # indicates attachment to V. In some embodiments,orembodiments, R5ais C1-4alkyl or C(O)C1-4alkyl. In some embodiments, R5ais methyl or acetyl.

[0114] In some embodiments of the compound of Formula (I) or (II), Ring 5 is 5- to 12- membered heteroaryl optionally substituted with one or more R5b, wherein each R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, Ring 5 is 5- to 6-membered heteroaryl optionally substituted with one or more R5b.RQ. In some embodiments, Ring 1 is , and Q is RQ. In some embodiments, Ring 1 65 ny-2730225220232001540 is , anQd Q is R . In some embodiments, Ring 1 some embodiments, Ring 4 is present.

[0116] In some embodiments, Ring 1 isQ, and Q is R . In some embodiments, Ring 1 is aQ Qnd Q is R . In some embodiments, Ring 1 is, and Q is R . In some embodiments, Ring 1 is , and Q iQs R . In some embodiments, Ring 1 isQ is RQ. In some embodiments, Ring 1, and Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments,, and Q is RQ. In some embodiments, Ring, and Q is RQ. In some embodiments, Ring 1 is, and Q is RQ. In some embodiments, Ring 1, and Q is RQ. In some embodiments, Ring 1 is , and Q is RQ. In some embodiments, Ring 4 is present.

[0117] In some embodiments of the compound of Formula (I) or (II), Ring 1 is a C4-8cycloalkyl optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5, and wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, 66 ny-2730225220232001540 N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 1 is a C5-8cycloalkyl optionally substituted with one or more R1, Ring 5 is a 4- to 12- membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 is a C6-8cycloalkyl optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom ofis optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5. In some embodiments,each of which is optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attachedto an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 is , Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is - - is attached to an annular nitrogen atomof Ring 5. In some embodiments, Ring 1 is , Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C to an annular nitrogen atom of Ring 5. In someembodiments, Ring 1 is , Ring 5 is a 4- to 12-membered heterocyclyl optionally 67 ny-2730225220232001540 substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is - C(O)- and is attached to an annular nitrogen atom of Ring 5.

[0118] In some embodiments, Q is Ring 5, and Ring 1, V, and Ring 5 are taken together to , ,Ring 4 is present.

[0119] In some embodiments of the compound of Formula (I) or (II), Ring 1 is a 4- to 8- membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5, and wherein each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 1 is a 5- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 is a 6- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered 68 ny-2730225220232001540 heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5.

[0120] In some embodiments, Ring 1 is unsubstituted with R1. In some embodiments, Ring 1 is substituted with one or more R1. In some embodiments, Ring 1 is substituted with 1, 2, or 3 R1. In some embodiments, each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments, each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, or N(Ry)C(O)C1-4haloalkyl. In some embodiments, each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, or CN.

[0121] In some embodiments of the compound of Formula (I) or Formula (II), the compound is of Formula (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), or (II-g):(II-f),(II-g),69 ny-2730225220232001540 or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and R, Ring 3, and Ring 4 are as defined for Formula (I). In some such embodiments, Ring 5 is 5- to 6-membered heterocyclyl optionally substituted with one or more R5a. In some such embodiments, Ring 5 is piperidinyl or piperazinyl, each of which is optionally substituted with one or more R5a. In some embodiments, Ring 4 is present.

[0122] In some embodiments of Formula (I) or Formula (II), or any related formula as applicable, when Ring 5 is present, Ring 5, V, and Ring 1 are taken together to form a group of Formula (A’), (B’), (C’), (D’), (E’), (F’), (G’), (H’), or (J’):

[0123] In some embodiments of the compound of Formula (I) or Formula (III), or any related formula as applicable, RQ, V, and Ring 1 are taken together to form a group of Formula (K’), (L’), (M’), (N’), or (O’): ,(i), 70 ny-2730225220232001540 and the compound is of Formula (IV), , orforegoing, wherein Ring A, X, Ring B, W, Ring C, Linker, U, Ring 2, V, Ring 1, R, Ring 3, and Ring 4 are as detailed herein for Formula (I). In some embodiments, Ring 4 is present. In some embodiments, Ring 2 is present. In some embodiments, Ring 2 and Ring 4 are each present. In some embodiments, Ring C is present. In some embodiments, Ring 2, Ring 4, and Ring C are each present.

[0125] In some embodiments of the compound of Formula (I), Q is of Formula (i),, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; 71 ny-2730225220232001540 V is a bond, -C1-4alkylene-, -C(O)-, -C(O)O-#, -OC(O)# -C1-4alkylene-C(O)-#, - C(O)N(RV)-#, -N(RV)C(O)-#, -OC(O)N(RV)-#, -N(RV)-C(O)O#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Ring A is selected from the group consisting of ,each of which is optionally substituted with one or moreC1-4alkyl or halo; X is a bond, -O-, -NH-, or -NHC(O)-;of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, -O-, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6alkylene; 72 ny-2730225220232001540 L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and L3is C1-10alkylene, C1-10alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1-10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, and R4ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, and R4bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and 73 ny-2730225220232001540 each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1 or Ring 2 to which it is attached, to form an amide or carbamate; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0126] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring A is selected from the group consisting, each of which is optionally substituted with C1-4alkyl or halo. In some embodiments, Ring Aoptionally substituted with C1-4alkyl or halo. In some embodiments, Ring A .

[0127] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), X is a bond, -O-, -NH-, or -NHC(O)-. In some embodiments, X is a bond or -NH-.

[0128] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring B is selected from the group 74 ny-2730225220232001540one or more or or some B is ,is optionally substituted with one or more halo or OH, wherein RDis H or C1-4alkyl, # indicates attachment to X, and ## indicates attachment to W. In some embodiments, Ring B isoptionally substituted with one or more halo or OH. In some embodiments, Ring B is.

[0129] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), W is a bond, -O-, -NH-, or -NHC(O)-. In some embodiments, W is a bond or -O-.

[0130] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring C is absent.

[0131] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- 75 ny-2730225220232001540 o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-c), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring C is present and is 4- to 12-membered heterocyclyl optionally substituted with one or more RC, wherein each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, Ring C is 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more RC. In some embodiments, Ring C is 5- to 6-membered heterocyclyl optionally substituted with one or more RC. In some embodiments, Ring C isoptionally substituted with one or more RC, wherein Y and Z are independently CH or N. In some embodiments, Ring C is piperidinyl or piperazinyl, each of which is optionally substituted with one or more RC. In some embodiments, Ring C is piperidinyl optionally substituted with one or more RC. In some embodiments, Ring C is piperazinyl optionally substituted with one or more RC. In some embodiments, Ring C is, each of which is optionally substituted with one or more RC. In some embodiments, Ring C,, , each of which is optionally substituted with onewherein # indicates attachment to W and ## indicates attachment to Linker. In someembodiments, Ring C is , , or , wherein # indicates attachment to W and ## indicates attachment to Linker.

[0132] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * 76 ny-2730225220232001540 indicates attachment to Ring C when Ring C is present, or attachment to W when Ring C is absent; and ** indicates attachment to U when Ring 2 is present, or attachment to V when Ring 2 is absent; L1is a bond or C1-6alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL, wherein each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; and L3is C1-10 alkylene, C1-10 alkylene- N(Ry), C(O)-C1-10alkylene, C(O)-C1-10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry).

[0133] In some embodiments of the compound of Formula (I’), (I), or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV- k), or (IV-l), Linker is a bond, -O-, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates attachment to Ring C when Ring C is present, or attachment to W when Ring C is absent; and ** indicates attachment to U when Ring 2 is present, or attachment to V when Ring 2 is absent; L1is a bond or C1-6 alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL, wherein each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; and L3is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1-10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry).

[0134] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry). In some embodiments of the compound of Formula (I) or (IV), Linker is a bond, C1-10alkylene, or C(O)C1-10alkylene.

[0135] In some embodiments of the compound of Formula (I) or (IV), Linker is a bond, C1-10alkylene, C(O)-C1-10alkylene, C1-6alkylene-C(O)-C1-10alkylene, 77 ny-2730225220232001540 C0-6alkylene-C(O)N(Ry)-C1-10alkylene, or is of the formula *-L1-L2-L3-**, wherein L1is a bond or C1-6 alkylene, L2is a piperidinyl ring or piperazinyl ring, and L3is C1-10 alkylene. In some embodiments, Linker is a bond, C1-2alkylene, C(O)-C1-2alkylene, or C1-2alkylene-C(O)N(Ry)-C1-10alkylene.

[0136] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-c), or (IV-d), Ring 2 is absent.

[0137] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b, wherein each R2ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; and each R2bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; and U is a bond. In some embodiments, the 4- to 12-membered heterocyclyl optionally substituted with one or more R2ais a nitrogen-containing heterocyclyl.

[0138] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b, wherein each R2ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, 78 ny-2730225220232001540 N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; and each R2bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; and U is C(O). In some embodiments, the 4- to 12-membered heterocyclyl optionally substituted with one or more R2ais a nitrogen-containing heterocyclyl.

[0139] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is C3-10 cycloalkyl optionally substituted with one or more R5a, wherein each R2ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 2 is C5-10 cycloalkyl optionally substituted with one or more R5a. In some embodiments, Ring 2 is C5-6cycloalkyl optionally substituted with one or more R5a. In some embodiments, Ring 2 is C6cycloalkyl optionally substituted with one or more R5a.

[0140] In some embodiments, Ring 2 is, , , each of which is optionally substituted with one or more R2a, wherein # indicates attachment to V.

[0141] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, wherein each R2ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 2 is 5- to 6-membered heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 is 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 is 5- to 6-membered 79 ny-2730225220232001540 nitrogen-containing heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 is piperidinyl or piperazinyl, each of which is optionally substituted with one or more R2a. In some embodiments, Ring 2 is 10- to 12-membered heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 ,each of which is optionally substituted withone or more wherein # indicates attachment to V. In some embodiments, Ring 2 iseach of which is optionally substituted with one or more R2a, wherein # indicates attachment to V. In some embodiments, Ring 2. In some embodiments, Ring 2 is. In some embodiments, Ring 2. In some embodiments, Ring.

[0142] In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I- o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is 5- to 12-membered heteroaryl optionally substituted with one or more R5b, wherein each R2bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, Ring 2 is 5- to 6-membered heteroaryl optionally substituted with one or more R5b.

[0143] In some embodiments of the compound of Formula (I’), or any related formula such as (I), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), each 80 ny-2730225220232001540 R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz),C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, each R2a, R3a, R4a, and R5ais C(O)Rw. In some embodiments, each R3ais C(O)Rw.

[0144] In some embodiments of the compound of Formula (I’), or any related formula such as (I), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, each R2b, R3b, R4b, and R5bis independently C(O)Rwor C1-4hydroxyalkyl. In some embodiments, each R2b, R3b, R4b, and R5bis independently C(O)Rw. In some embodiments, each R2b, R3b, R4b, and R5bis independently C1-4hydroxyalkyl. In some embodiments, each R3bis independently C(O)Rwor C1-4hydroxyalkyl. In some embodiments, each R3bis independently C(O)Rw. In some embodiments, each R3bis independently C1-4hydroxyalkyl. In some embodiments, each.

[0145] In some embodiments, each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl. In some embodiments, each Rwis independently 3- to 10-membered cycloalkyl. In some embodiments, each Rwis independently phenyl optionally substituted with halo. In some embodiments, each Rwis phenyl optionally substituted with fluoro or chloro. In some embodiments, each Rwis phenyl optionally substituted with fluoro. In some embodiments, each Rwis phenyl optionally substituted with chloro. In some embodiments, each Rwis independently 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl. In some embodiments, each Rwis 4- to 12-membered heterocyclyl optionally substituted with hydroxyl. In some embodiments, each Rwis 4- to 12-membered heterocyclyl optionally substituted with C1-4hydroxyalkyl. In some embodiments, each Rwis 4- to 12-heterocyclyl optionally substituted with C1-4aminoalkyl. In some embodiments, Rwis , 81 ny-2730225220232001540.

[0146] In some embodiments, each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments, each Ryand Rzis independently 3- to 10-membered cycloalkyl. In some embodiments, one of Ryand Rzis hydrogen and the other is 3- to 10-membered cycloalkyl. In some embodiments, one of Ryand Rzis hydrogen and the other is cyclopropyl.

[0147] In some embodiments, each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, each RVis independently H or C1-4alkyl. In some embodiments, each RVis independently H or C1-2alkyl. In some embodiments, each RVis independently H or methyl. In some embodiments, each RVis independently H or ethyl. In some embodiments, each RVis H. In some embodiments, each RVis methyl. In some embodiments, each RVis ethyl.

[0148] In some embodiments of Formula (IV), Ring C, U, and Ring 2 are present, and the compound is of Formula (IV-a). In some embodiments of Formula (IV), U and Ring 2 are present, and Ring C is absent, and the compound is of Formula (IV-a). In some embodiments, Ring C is present, and U and Ring 2 are absent, and the compound is of Formula (IV-c). In some embodiments, Ring C, U, and Ring 2 are absent, and the compound is of Formula (IV- d). In some embodiments, the compound of Formula (I) or (IV) is of Formula (IV-a), (IV-a), (IV-c), or :(IV-b), 82 ny-2730225220232001540(IV-d), wherein Ring A, X, Ring B, W, Ring C, Linker, U, Ring 2, V, Ring 1, R, Ring 3, and Ring 4 are as described herein for Formula (I).

[0149] In some embodiments of Formula (I), Formula (IV), or any related formula such as Formula (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), when Ring 2 is present, Ring 2, V, and Ring 1 are taken together to form a group of Formula (A), (B), (C), (D), (E), (F), (G), (H), or (J):, . In some such embodiments, Ring 2, V, and Ring 1 are taken together to form a group of Formula (C), (D), or (E). In some such embodiments, when Ring 2 is present, Ring 2, V, and Ring 1(K), (L), (M), 83 ny-2730225220232001540. In some such embodiments, when Ring 2 is present, Ring 2, V, and Ring 1 are taken together to form a group of Formula (O), (P), (Q), or (R), or a stereoisomer thereof:(R).

[0150] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, and V is a bond or C1-4alkylene. In some embodiments, Ring 1 is a saturated 5- to 6-membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, and V is a bond or C1-4alkylene. In someembodiments, Ring 1 is , optionally substituted with one or more R1, wherein # indicates attachment to V, which is a bond or C1-4alkylene. In some embodiments, Ring 1 isor , of which is optionally or more R1, andV is a bond or C1-4alkylene. In some is , and V is a bond orC1-4alkylene. In some embodiments, Ring 1 is , and V is a bond or C1-4alkylene.

[0151] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (IV-a), (IV-a), (IV-c), or (IV-d), Ring 1 is a saturated 4- to 8- 84 ny-2730225220232001540 membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is -C(O)- or -C1-4alkylene-C(O)-. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is -C(O)- or -C1- 4alkylene-C(O)-. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 6- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is -C(O)- or -C1-4alkylene-C(O)-. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1, and V is -C(O)- or -C1-4alkylene-C(O)-. In some embodiments, Ring 1 iswherein # indicates attachment to V, each of which is optionally substituted with one or more R1, and C(O)-. In some embodiments, Ring 1 is, wherein # indicates attachment to V, each of which is optionally substituted with one or more R1, and V is -C(O)- or -C1-4alkylene-C(O)-. In some embodiments, Ring 1, and V is -C(O)- or -C1-4alkylene-C(O)-. In some embodiments, Ring, C(O)-. In some embodiments, Ring, - - - - .

[0152] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (IV-a), (IV-a), (IV-c), or (IV-d), Ring 1 is a C4-8cycloalkyl optionally substituted with one or more R1, and V is -C(O)N(RV)-#, -N(RV)C(O)-#, -C1-4alkylene- C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#.

[0153] In some embodiments of the compound of Formula (I), (IV), or any related formula such as (IV-a) or (IV-a), Ring 1 is a C4-8cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. 85 ny-2730225220232001540 In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12- membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is, , , each of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atomof Ring 2. In some embodiments, Ring 1 is , Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is - attached to an annular nitrogen atomof Ring 2. In some embodiments, Ring 1 is , Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. 86 ny-2730225220232001540

[0154] In some embodiments of the compound of Formula (I), (IV), or any related formula such as (IV-a) or (IV-a), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring,of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1, , , , , of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is - attached to an annular nitrogen atomof Ring 2. In some embodiments, Ring 1 is , Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a C4-8cycloalkyl optionally substituted with one or more R2a, and V is -C(O)N(RV)-#, wherein # indicates the point of 87 ny-2730225220232001540 attachment to Ring 1. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a C5-8 cycloalkyl optionally substituted with one or more R2a, and V is -C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a C6-8 cycloalkyl optionally substituted with one or more R2a, and V is -C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1. In some embodiments, Ring 1 is a cyclohexyl optionally substituted with one or more R1, Ring 2 is a cyclohexyl optionally substituted with one or more R2a, and V is -C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1.

[0155] In some embodiments of the compound of Formula (I) or Formula (IV), Ring 2 is present and the compound is of Formula (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV- l):88 ny-2730225220232001540 (IV-j),(IV-l).

[0156] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6- membered heterocyclyl optionally substituted with one or more R3a, phenyl optionally substituted with one or more R3b, or 5- to 6-membered heteroaryl optionally substituted with one or more R3b, wherein each R3ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo, and each R3bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, each R3ais independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, CN, or oxo. In some embodiments, each R3ais oxo. In some embodiments, each R3bis independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, or CN.

[0157] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a.

[0158] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), 89 ny-2730225220232001540 (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 4- to 6-membered heterocyclyl optionally substituted with one or more R3a. In some embodiments of the compound of Formula (I), Ring 3 is 4- to 6-membered nitrogen- containing heterocyclyl optionally substituted with one or more R3a. In some embodiments, Ring 3 is pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. In some embodiments, Ring 3 is, each of which is optionally substituted with one or more R3a, wherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present. In some embodiments, Ring 3 is, , , each of which is optionally substituted with one or more R3a. In some embodiments, Ring 3,, , , or , wherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present.

[0159] In some embodiments of the compound of Formula (I), (II), (III), or (IV), or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), optionally substituted with one or more R3b. In some embodiments, Ring 3is optionally substituted with one or more R3b. In some embodiments, Ring 3 is 90 ny-2730225220232001540 .acetyl, or CN. In some embodiments, each R3bis independently halo, methyl, or OCH3.

[0160] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 5- to 6-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is 5- to 6-membered nitrogen-containing heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is 6-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is 5-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is pyrazolyl optionally substituted with one or more R3b. In some embodiments, Ring 3 is, , , each of which is optionally substituted with one or more R3b. In some embodiments, Ring 3 is, , , , or , each of which is optionally substituted with one or more R3b, wherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates4, when present. In some embodiments, Ring 3 is or, wherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present. In some embodiments, Ring 3 is 6-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is pyridinyl, pyrimidinyl, or pyrazinyl optionally substituted with one or more R3b. 91 ny-2730225220232001540

[0161] In some embodiments, Ring 3 is , each of which is optionally substituted with one or moreto the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present.

[0162] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is other than 5-membered heteroaryl, and Ring 4 is absent. In some such embodiments, Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 6-membered heteroaryl optionally substituted with one or more R3b, and Ring 4 is absent. In some such embodiments, Ring 3 is 3- to 6- membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; or phenyl optionally substituted with one or more R3b; and Ring 4 is absent.

[0163] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is present. In some embodiments, Ring 4 is present and is unsubstituted. In some embodiments, Ring 4 is present and is unsubstituted or substituted with halo. In some embodiments, Ring 4 is phenyl substituted with halo. In some embodiments, Ring 4 is phenyl substituted with fluoro.

[0164] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is present and is a monocyclic ring selected from the group consisting of 3- to 6- membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b, wherein each R4ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, 92 ny-2730225220232001540 C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo, and each R4bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx, wherein when Ring 3 is 5- membered heteroaryl, Ring 4 is not cycloalkyl or tetrahydropyranyl. In some embodiments, each R4ais independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, CN, or oxo. In some embodiments, each R4ais methyl or acetyl. In some embodiments, each R4bis independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, or CN.

[0165] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is 3- to 6-membered cycloalkyl optionally substituted with one or more R4aand Ring 3 is not 5-membered heteroaryl. In some embodiments, Ring 4 is 4- to 6-membered cycloalkyl optionally substituted with one or more R4a, and Ring 3 is not 5-membered heteroaryl. In some embodiments, Ring 4 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl optionally substituted with one or more R4a, and Ring 3 is not 5-membered heteroaryl. In some embodiments, Ring 4 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and Ring e is not 5-membered heteroaryl. In some embodiments, Ring 4 is cyclobutyl, cyclopentyl, or cyclohexyl, and Ring 3 is not 5-membered heteroaryl.

[0166] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as ((I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, wherein when Ring 3 is 5-membered heteroaryl, Ring 4 is not tetrahydropyranyl. In some embodiments, Ring 4 is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a. In some embodiments, Ring 4 is 5- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a. In some embodiments, Ring 4 is pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one or more R4a. In some embodiments, Ring 4 is pyrrolidinyl or 93 ny-2730225220232001540 piperidinyl, each of which is optionally substituted with one or more R4a. In some issome embodiments,each R4ais independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, CN, or oxo. In some embodiments, each R4ais methyl or acetyl.

[0167] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is phenyl optionally substituted with one or more R4b. In some embodiments, Ring 4 isIn some embodiments, each R4ais independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, or CN. In some embodiments, each R4ais halo, methyl, or OCH3.

[0168] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 4 is 5- to 6-membered nitrogen-containing heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 4 is 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 4 is pyridinyl or pyrazinyl, each of which R4b. In someembodiments, Ring 4 is , , , or , each of which is 94 ny-2730225220232001540 optionally substituted with one or more R4b. In some embodiments, Ring 4 ,each of which is optionally substituted with one or more R4b. In someembodiments, Ring 4 .

[0169] In some embodiments, Ring 4 isoptionally substituted with one or more R4b.

[0170] In some embodiments, Ring 4 is,is optionally substituted with one or more R4a.

[0171] In some embodiments, Ring 4 is, , , is optionally substituted with one or more R4a.

[0172] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6- membered heterocyclyl optionally substituted with one or more R3a, phenyl optionally substituted with one or more R3b, or 6-membered heteroaryl optionally substituted with one or more R3b; and Ring 4 is absent. In some embodiments of the compound of Formula (I), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6- membered heterocyclyl optionally substituted with one or more R3a, or phenyl optionally substituted with one or more R3b; and Ring 4 is absent.

[0173] In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), 95 ny-2730225220232001540 (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 5-membered heteroaryl, and Ring 4 is present and is not cycloalkyl or tetrahydropyranyl. In some embodiments of the compound of Formula (I), Ring 3 is 5- membered heteroaryl, and Ring 4 is present and is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, or 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments of the compound of Formula (I), Ring 3 is 5-membered heteroaryl, and Ring 4 is present and is phenyl optionally substituted with one or more R4b, or 5- to 6- membered heteroaryl optionally substituted with one or more R4b.

[0174] In some embodiments, Ring 3 is phenyl, and Ring 4 is present and is 4- to 6- membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, or 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 3 is phenyl and Ring 4 is present and is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a. In some embodiments, Ring 3 is phenyl and Ring 4 is present

[0175] In some embodiments of the compound of Formula (I), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I- q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 4 is absent and Q is of Formula (i). In some embodiments, Ring 4 is present and Q is of Formula (i).

[0176] In some embodiments, Ring 4 is absent. In some embodiments, Ring 4 is present.

[0177] In some embodiments of the compound of Formula (I), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV- e), and C together are:, , 96 ny-2730225220232001540RC, and wherein Y and Z are independently CH or N. In some embodiments, Ring A, X, Ring B, ,, , or , wherein eachis optionally substituted with one or more RC, and wherein Y and Z are 97 ny-2730225220232001540 independently CH or N. In some embodiments, Ring A, X, Ring B, W, and C together are: ormore and wherein Y and Z are independently CH or N. In some embodiments, Ring A,is optionally substituted with one or more RC, and wherein Y and Z are independently CH or N.

[0178] In some embodiments, Ring A, X, Ring B, W, and C together are:, optionally substituted with R2b, wherein eachis optionally substituted with one or more RC, and wherein Y and Z are independently CH or N.

[0179] In some embodiments, when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; and when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is -OC(O)#, then RQis not tert-butyl. In some embodiments, when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl. In some embodiments, when Ring 1 is 8- membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is -OC(O)#, then RQis not tert-butyl.

[0180] It is to be understood that all embodiments of Formula (I) and sub-formulas thereof, also apply to Formulas (II), (III), and (IV), including all sub-formulas, and variations thereof, 98 ny-2730225220232001540 as applicable. Further, the present disclosure contemplates combinations of features as disclosed herein, as if each were individually listed. Exemplary combinations of features are provided herein but are not to be construed as limiting.

[0181] It is to be understood that all embodiments of Formula (I) and sub-formulas thereof, also apply to Formulas (I’), (II), (III), and (IV), including all sub-formulas, and variations thereof, as applicable. Further, the present disclosure contemplates combinations of features as disclosed herein, as if each were individually listed. Exemplary combinations of features are provided herein but are not to be construed as limiting.

[0182] Representative compounds are listed in Table 1 and Table 2.

[0183] In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 1 or Table 2. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 1. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 2.

[0184] In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91 of Table 1, and compounds 44-90 of Table 2. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91-274 of Table 1, and compounds 44-90 and 275-605 of Table 2. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a 99 ny-2730225220232001540 pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43, 91- 274, and 606-631 of Table 1, and compounds 44-90, 275-605, and 632-705 of Table 2. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91 of Table 1. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91-274 of Table 1. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43, 91-274, and 606-631 of Table 1. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 44-90 of Table 2. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 44-90 and 275-605 of Table 2. In some embodiments of a compound of Formula (I’) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 44- 90, 275-605, and 632-705 of Table 2.

[0185] T bl 1 R t ti C d f F l I’ I II d III CNo. 100 ny-2730225220232001540 1 4-((4-([1,1'-biphenyl]-3- - - - e101 ny-2730225220232001540 6 1-(4-((4-([1,1'-biphenyl]-3- - - - - - - - - -102 ny-2730225220232001540 11 (4-((4-([1,1'-biphenyl]-3- - -103 ny-2730225220232001540 16 4-((4-([1,1'-biphenyl]-3- -104 ny-2730225220232001540 22 3-((4-([1,1'-biphenyl]-3- -105 ny-2730225220232001540 28 trans-3-((5-chloro-4-(4-carboxamide 106 ny-2730225220232001540 37 (S)-1-(3-((5-chloro-4-(3- i -carboxamide 107 ny-2730225220232001540 93 cis-N-((1s,4s)-4-((5-chloro- - - - - -cyclohexyl)acetamide 108 ny-2730225220232001540 101 trans-(1r,4r)-4-((5-chloro- - -carboxamide 109 ny-2730225220232001540 109 1-(4-((5-chloro-4-(1- - -mide 110 ny-2730225220232001540 117 trans-(1r,4r)-4-((5-chloro- -carboxamide 111 ny-2730225220232001540 124 trans-N-(4-((5-chloro-4-(1- - - -mide 112 ny-2730225220232001540 131 cis-(1s,4s)-4-((5-chloro-4- - - -113 ny-2730225220232001540 138 cis-(1s,4s)-4-((5-chloro-4-mide 114 ny-2730225220232001540 146 O trans-(1r,4r)-4-((5-chloro- -mide 115 ny-2730225220232001540 155 trans-(1r,4r)-4-((5-chloro- -116 ny-2730225220232001540 162 trans-(1r,3r)-3-((5-chloro-carboxylate 117 ny-2730225220232001540 169 1-(4-((5-fluoro-4-(3- - -118 ny-2730225220232001540 177 cis-3-((5-fluoro-4-(2-(2- - - - -119 ny-2730225220232001540 189 1-(1-(2-((1-acetylpiperidin- -120 ny-2730225220232001540 197 trans-(R)-1-(2-((4- - - - - - - - - - -121 ny-2730225220232001540 205 1-(4-((5-fluoro-4- - e - -122 ny-2730225220232001540 213 (R)-1-(4-((5-fluoro-4-(3- - - e123 ny-2730225220232001540 221 1-(3-(2-((1-acetylpiperidin- - - - - e -hydroxypyrrolidin-2-one 124 ny-2730225220232001540 229 trans-4-((5-fluoro-4-(3-(6- - - - -carboxamide 125 ny-2730225220232001540 237 (4R)-1-[3-[2-[(1-acetyl-4- - - -carboxamide 126 ny-2730225220232001540 245 trans-4-((5-fluoro-4-(3-(2- - - -a mide 127 ny-2730225220232001540 253 H O trans-N-((1r,4r)-4-((5- N F - - - - -mide 128 ny-2730225220232001540 261 trans-N-(4-((5-fluoro-4-(2- - - - - - - r r rcarboxamide 129 ny-2730225220232001540 270 trans-N-(4-((5-fluoro-4-(6- - - - d - dmide 130 ny-2730225220232001540 610 trans-4-((4-([1,1'- - - - -131 ny-2730225220232001540 618 trans-(1r,4r)-4-((4-(3- - - - - - -mide 132 ny-2730225220232001540 627 cis-3-((5-fluoro-4-(6-(3- - - - - -

[0186] Table 2: Representative Compounds of Formula (I'), (I), and (IV)- 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 133 ny-2730225220232001540 45yl)phenyl)amino)piperidine-2,6-dione 134 ny-2730225220232001540 49methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 135 ny-2730225220232001540 53yl)phenyl)amino)piperidine-2,6-dione 136 ny-2730225220232001540 58oxoisoindolin-2-yl)piperidine-2,6-dione 137 ny-2730225220232001540 62 -yl)oxy)acetamide 138 ny-2730225220232001540 672-yl)piperidine-2,6-dione 139 ny-2730225220232001540 722,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 140 ny-2730225220232001540 76141 ny-2730225220232001540 cis-3-(5-((1-(2-(1-(3-((4-([1,1'-biphenyl]-3-yl)-5-chloropyrimidin-2- - -oxoisoindolin-2-yl)piperidine-2,6-dione 142 ny-2730225220232001540 872,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 143 ny-2730225220232001540 276 Oyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4- 144 ny-2730225220232001540 yl)ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-hydroxypiperidin-1-yl)-3-fluorophenyl)piperidine-2,6-dione 145 ny-2730225220232001540 283methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 146 ny-2730225220232001540 287oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione 147 ny-2730225220232001540 291 -oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 148 ny-2730225220232001540 295149 ny-2730225220232001540 3-(6-(1-(2-(1-(cis-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin- -yl)amino)cyclohexyl)acetamide 150 ny-2730225220232001540 302 -bipiperidine]-4-carboxamide 151 ny-2730225220232001540 306 -yl)ethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 152 ny-2730225220232001540 309yl)ethyl)piperidin-4-yl)-3-fluorophenyl)amino)piperidine-2,6-dione 153 ny-2730225220232001540 312 -methyl-1H-indazol-3-yl)piperidine-2,6-dione 154 ny-2730225220232001540 316 Oyl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 155 ny-2730225220232001540 319 -156 ny-2730225220232001540 trans-3-((3-fluoro-4-(1-(2-(1-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)- - -oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 157 ny-2730225220232001540 326yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)propanamide 158 ny-2730225220232001540 329oxoethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 159 ny-2730225220232001540 332 -yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 160 ny-2730225220232001540 335 -yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 161 ny-2730225220232001540 338 -yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione 162 ny-2730225220232001540 342 -carboxamide 163 ny-2730225220232001540 345 - -- 4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 164 ny-2730225220232001540 348 e -yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 165 ny-2730225220232001540 351oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 166 ny-2730225220232001540 354yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 167 ny-2730225220232001540 357 -oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide 168 ny-2730225220232001540 361yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 169 ny-2730225220232001540 365 -yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 170 ny-2730225220232001540 369oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 171 ny-2730225220232001540 373172 ny-2730225220232001540 trans-2-(1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-4-yl)-173 ny-2730225220232001540 trans-(1r,4R)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 174 ny-2730225220232001540 385 O - -yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione 175 ny-2730225220232001540 388 -piperidyl]methyl]-4-piperidyl]-3-fluoro-anilino]piperidine-2,6-dione 176 ny-2730225220232001540 391 Oyl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 177 ny-2730225220232001540 395 - -yl)methyl)piperazin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione 178 ny-2730225220232001540 399 O -1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 179 ny-2730225220232001540 402carboxamide 180 ny-2730225220232001540 405 Oyl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione 181 ny-2730225220232001540 408 -- yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide 182 ny-2730225220232001540 412 Oyl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione 183 ny-2730225220232001540 415yl)methyl)piperazin-1-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione 184 ny-2730225220232001540 418185 ny-2730225220232001540 trans-(1r,4R)-N-((1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-dione 186 ny-2730225220232001540 424 Opiperidyl]methyl]piperazin-1-yl]anilino]piperidine-2,6-dione 187 ny-2730225220232001540 427188 ny-2730225220232001540 3-((3-fluoro-4-(4-((4-(trans-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3- -yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)piperidine-4-carboxamide 189 ny-2730225220232001540 434190 ny-2730225220232001540 trans- (1r,4R)-N-((1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-- 2-yl)amino)cyclohexane-1-carboxamide 191 ny-2730225220232001540 441hydroxy-[1,4'-bipiperidine]-4-carboxamide 192 ny-2730225220232001540 445 O -yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide 193 ny-2730225220232001540 448H O 194 ny-2730225220232001540 trans-N-(1'-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3',3'-difluoro-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide 195 ny-2730225220232001540 455 - -carboxamide 196 ny-2730225220232001540 458 OH 197 ny-2730225220232001540 trans-(1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2- -yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 198 ny-2730225220232001540 466, dione 199 ny-2730225220232001540 471200 ny-2730225220232001540 trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2- -carboxamide 201 ny-2730225220232001540 480202 ny-2730225220232001540 trans-3-[3-fluoro-4-[4-[[4-fluoro-1-[4-[[5-fluoro-4-(3-phenylphenyl)1(2H)-yl)phenyl)pyrimidin-2-yl)amino)-N-methylcyclohexane-1-carboxamide 203 ny-2730225220232001540 489 -204 ny-2730225220232001540 trans-3-[3-fluoro-4-[4-[[1-[4-[[5-fluoro-4-[3-(1-piperidyl)phenyl]pyrimidin-2- - - - -205 ny-2730225220232001540 trans-N-(4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2- -206 ny-2730225220232001540 trans-1'-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3',3'-difluoro-N- - -207 ny-2730225220232001540 trans-2-((1r,4R)-4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 208 ny-2730225220232001540 509 -carboxamide 209 ny-2730225220232001540 512yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 210 ny-2730225220232001540 516 -oxazinan-3-yl)pyridin-2-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 211 ny-2730225220232001540 520[1,4'-bipiperidine]-4-carboxamide 212 ny-2730225220232001540 524yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 213 ny-2730225220232001540 528 -214 ny-2730225220232001540 trans-N-(1'-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4'-215 ny-2730225220232001540 trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1- -carboxamide 216 ny-2730225220232001540 540 Oyl)amino)cyclohexyl)-[1,4'-bipiperidine]-4-carboxamide 217 ny-2730225220232001540 543 Ocarboxamide 218 ny-2730225220232001540 546yl)pyridin-4-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 219 ny-2730225220232001540 550 edione 220 ny-2730225220232001540 554- yl)cyclohexyl)cyclohexane-1-carboxamide 221 ny-2730225220232001540 558 - -222 ny-2730225220232001540 trans-2-((1r,4R)-4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2- -223 ny-2730225220232001540 trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2- e224 ny-2730225220232001540 trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2- - e225 ny-2730225220232001540 trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2- - - -226 ny-2730225220232001540 trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(3-dione 227 ny-2730225220232001540 583oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 228 ny-2730225220232001540 587 Ooxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 229 ny-2730225220232001540 591yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide 230 ny-2730225220232001540 594bipiperidine]-4-carboxamide 231 ny-2730225220232001540 597 O -yl)amino)cyclohexyl)-[1,4'-bipiperidine]-4-carboxamide 232 ny-2730225220232001540 600 -603 233 ny-2730225220232001540 trans-(1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-234 ny-2730225220232001540 6-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)piperidine-1-carboxylate 235 ny-2730225220232001540 638 -fluorophenyl)piperidin-1-yl)ethyl)-4-hydroxypiperidine-1-carboxylate 236 ny-2730225220232001540 642- 4-carboxamide 237 ny-2730225220232001540 646- [1,4'-bipiperidine]-4-carboxamide 238 ny-2730225220232001540 650 -yl)amino)cyclohexyl)-N-methylcyclohexane-1-carboxamide 239 ny-2730225220232001540 654 e -morpholinophenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 240 ny-2730225220232001540 658 -morpholinophenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide 241 ny-2730225220232001540 662 - -yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 242 ny-2730225220232001540 666243 ny-2730225220232001540 3-((3-fluoro-4-(4-((trans-4-(4-((5-fluoro-4-(3-morpholinophenyl) pyrimidin-2- ) -fluorophenyl)piperazin-1-yl)piperidine-1-carboxylate 244 ny-2730225220232001540 675 -[1,4'-bipiperidine]-1'-carboxylate 245 ny-2730225220232001540 679 eyl)phenyl]pyrimidin-2- 246 ny-2730225220232001540 yl]amino]cyclohexanecarbonyl]cyclohexyl]methyl]piperazin-1- e efluorophenyl)piperazin-1-yl)piperidine-1-carboxylate 247 ny-2730225220232001540 688dione 248 ny-2730225220232001540 692 e -, 3'-fluoro-[1,4'-bipiperidine]-1'-carboxylate 249 ny-2730225220232001540 6961(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidine-1-carboxylate 250 ny-2730225220232001540 700 - -, yl)amino)cyclohexyl)acetamide 251 ny-2730225220232001540 704 -carboxamide Pharmaceutical Compositions

[0187] Another aspect of the present invention is directed to a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I’), (I), (II), (III), (IV), or any 252 ny-2730225220232001540 related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I- ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable carriers or excipients. Representative pharmaceutically acceptable carriers and excipients are disclosed in, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000; Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York; and Handbook of Pharmaceutical Excipients (3rded.) ed. A. H. Kibbe, Amer. Pharm. Assoc., 2000; each of which is incorporated herein by reference in its entirety).

[0188] Compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be formulated into a composition in accordance with conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York, each of which is incorporated herein by reference in its entirety). The type of formulation depends on the mode of administration which may include, for example, enteral administration, parenteral administration, and topical administration.

[0189] In some embodiments, the compounds are formulated for oral or intravenous (i.v.) administration (e.g., systemic i.v. injection). In some embodiments, the compounds are formulated for oral administration. In some embodiments, the compounds are formulated for intravenous (i.v.) administration.

[0190] Accordingly, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I- ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), 253 ny-2730225220232001540 (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be formulated into a solid composition, a liquid composition , a semi-solid composition, or as a gas composition.

[0191] Solid dosage forms include capsules (e.g., gelatin capsules or hard-shell capsules), tablets, pills, powders, and granules.

[0192] Liquid dosage forms for oral administration include solutions, suspensions, emulsions, micro-emulsions, and syrups.

[0193] Injectable preparations for parenteral administration may be formulated according to standard techniques, using dispersing / wetting and suspending agents. The sterile injectable preparation may be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent.

[0194] The compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be formulated for administration by inhalation..

[0195] Compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be formulated for topical administration which as used herein, refers to intradermal administration to the epidermis.

[0196] In some embodiments, the topical formulations may also include an excipient, such as a penetration enhancing agent. See, e.g., Percutaneous Penetration Enhancers, Maibach H. I. and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, Fla. (1995), and Buyuktimkin et al., Chemical Means of Transdermal Drug Permeation Enhancement in Transdermal and Topical Drug Delivery Systems, Gosh T. K., Pfister W. R., Yum S. I. (Eds.), Interpharm Press Inc., Buffalo Grove, Ill. (1997), each of which is incorporated herein by reference in its entirety. Dosage Amounts 254 ny-2730225220232001540

[0197] The total daily dosage of the compounds thereof may be determined in accordance with standard medical practice (see, e.g., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173, 2001, which is incorporated herein by reference in its entirety). Methods of Use

[0198] In some aspects, provided is a method of treating a disease or disorder comprising reducing the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to a subject in need thereof. In some aspects, provided is a method of treating a disease or disorder comprising reducing the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, which method comprises administration of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to a subject in need thereof. In some aspects, provided is a method of treating a disease or disorder comprising reducing the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administration of (a) a therapeutically effective amount of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), 255 ny-2730225220232001540 (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a therapeutically effective amount of compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II- c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to a subject in need thereof. In some aspects, provided is a method of treating a disease or disorder comprising reducing the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, which method comprises administration of a therapeutically effective amount of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II- c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to a subject in need thereof. In some embodiments, the methods comprise reducing the level or activity of PIP4K2C.

[0199] In some embodiments, the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C in the subject is reduced by between about 5% and about 100% as compared to an untreated control subject, e.g., at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% as compared to an untreated control subject. In some embodiments, the level or activity of at least PIP4K2C is reduced.

[0200] In some embodiments, degradation or depletion of PIP4K2A, PIP4K2B, and / or PIP4K2C proteins (e.g., PIP4K2C protein) treats cancer. In some embodiments, degradation or depletion of PIP4K2A, PIP4K2B, and / or PIP4K2C proteins (e.g., PIP4K2C protein) is useful for diagnosing cancer. In some cases, the PIP4K2C protein is degraded compared to PIP4K2A and PIP4K2B proteins. In some embodiments, degradation or depletion of the 256 ny-2730225220232001540 PIP4K2A protein, the PIP4K2B protein, and / or the PIP4K2C protein (for instance, degradation or depletion of the PIP4K2C protein) enhances immune responses against cancer and tumors. In some embodiments, depletion or degradation of PIP4Ks, (for instance, degradation or depletion of the PIP4K2B protein) treats insulin resistance.

[0201] In some embodiments, the compounds or compositions herein reduce the level of PIP4K2B in a patient suffering from insulin resistance or suspected of suffering from insulin resistance. In some embodiments, the compounds or compositions herein decrease the level of PIP4K2C in a patient suffering from cancer, immune deficiency, autoimmune disease, or infectious disease, or a combination thereof, or suspected of suffering from cancer, immune deficiency, autoimmune disease, or infectious disease, or a combination thereof.

[0202] In some aspects, provided is a method of enhancing immune function in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some aspects, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some aspects, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject a therapeutically effective amount of (a) a compound of Formula (I’), (I), (II), 257 ny-2730225220232001540 (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I- h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I- y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I- g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I- x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II- e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some aspects, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject a therapeutically effective amount of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0203] In some embodiments, immune function in the subject is enhanced by between about 5% and about 100% as compared to an untreated control subject, e.g., at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% as compared to an untreated control subject.

[0204] In some aspects, provided is a method of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one other of PIP4K2A, PIP4K2B, and PIP4K2C or phosphatidylinositol-4-phosphate 5-kinase (PIP5K) in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), 258 ny-2730225220232001540 (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II- c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II- c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some aspects, provided is a method of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one other of PIP4K2A, PIP4K2B, and PIP4K2C or phosphatidylinositol-4-phosphate 5- kinase (PIP5K) in a subject in need thereof, comprising administering to a subject a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, provided is a method of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one other of PIP4K2A, PIP4K2B, and PIP4K2C or phosphatidylinositol-4-phosphate 5-kinase (PIP5K) in a subject in need thereof, comprising administering a therapeutically effective amount of (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- 259 ny-2730225220232001540 ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one other of PIP4K2A, PIP4K2B, and PIP4K2C or phosphatidylinositol-4-phosphate 5-kinase (PIP5K) in a subject in need thereof, comprising administering to a subject a therapeutically effective amount of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II- c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, provided is a method of stimulating the immune system comprising reducing scaffolding or interaction of PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5-kinase (PIP5K) in a subject in need thereof. The reduction in the scaffolding or interaction may stimulate the immune system. In some embodiments, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, are components of vaccines. In some embodiments, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I- j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I- z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II- g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing are vaccine adjuvants.

[0205] In some embodiments, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I- 260 ny-2730225220232001540 ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat a viral infection. In some embodiments, provided is a method of treating a viral infection in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I- h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I- y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II- f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I- g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I- x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II- e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating a viral infection in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject. In some embodiments, the compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with a vaccine for viral infections to enhance the immune response.

[0206] In some embodiments, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I- ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat 261 ny-2730225220232001540 bacterial infections (e.g., necrotizing soft tissue infection). In some embodiments, provided is a method of treating a bacterial infection in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating a bacterial infection in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject. In some embodiments, the bacterial infection comprises necrotizing soft tissue infection.

[0207] In some embodiments, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I- ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat diseases or disorders associated with at least one of PIP4K2A, PIP4K2B, and PIP4K2C. In some embodiments, provided is a method of treating a disease or disorder associated with at least one of PIP4K2A, PIP4K2B, and PIP4K2C in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such 262 ny-2730225220232001540 as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating a disease or disorder associated with at least one of PIP4K2A, PIP4K2B, and PIP4K2C in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I- w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II- d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject. In some embodiments, the disease or disorder is associated with PIP4K2C. In some embodiments, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I- j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I- z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II- g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat diseases or disorders associated with PIP4K2C.

[0208] In some embodiments, compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I- ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat cell 263 ny-2730225220232001540 proliferative diseases or disorders. In some embodiments, provided is a method of treating a cell proliferative disease or disorder in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating a cell proliferative disease or disorder in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I- t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject.

[0209] Exemplary non-cancerous (e.g., cell proliferative) a diseases or disorders that may be amenable to treatment with the compounds or compositions of the present invention include inflammatory, autoimmune, neurodegenerative, heart, viral, metabolic, and genetic diseases or conditions, and chronic and acute kidney diseases or injuries.

[0210] In some embodiments, the compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I- ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat neurodegenerative diseases and disorders. In some embodiments, provided is a method of 264 ny-2730225220232001540 treating a neurodegenerative disease or disorder in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating a neurodegenerative disease or disorder in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject.

[0211] In some embodiments, the compounds of Formula (I’), (I), (II), (III), (IV), or any related formula as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I- m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat autoimmune diseases and disorders. In some embodiments, provided is a method of treating an autoimmune disease or disorder in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) 265 ny-2730225220232001540 (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating an autoimmune disease or disorder in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject. In some embodiments, the disease or disorder is fibrosis.

[0212] In some embodiments, the compounds of Formula (I’), (I), (II), (III), (IV), or any related formula as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I- m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, are used to promote wound healing.

[0213] In other embodiments, the methods are directed to treating subjects having cancer. Compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing treat carcinomas (including primary and metastatic tumors), sarcomas, melanomas, and hematological cancers such as leukemia, 266 ny-2730225220232001540 lymphoma and multiple myeloma. In some embodiments, provided is a method of treating a carcinoma, sarcoma, melanoma, or hematological cancer in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating carcinoma, sarcoma, melanoma, or hematological cancer in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject. The subject may be an adult or pediatric subject. Tumors may be vascularized, not substantially vascularized, or non-vascularized. In some embodiments, tumors are solid tumors. In some embodiments, the cancer is acute myelocytic leukemia. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is lung cancer.

[0214] In some embodiments, provided herein is a method of degrading PIP4K2C using a compound of Formula (I’), or any related formula, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, provided herein is a method of degrading PIP4K2C using a compound of Formula (I’), or any related formula, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is formula (i): 267 ny-2730225220232001540 , (i). In some embodiments, providedherein is a method of degrading PIP4K2C using a compound of Formula (I’), (I), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0215] In some embodiments, provided herein is a method of inhibiting PIP4K using a compound of Formula (I’), or any related formula, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, provided herein is a method of inhibiting PIP4K using a compound of Formula (I’), or any related formula, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is RQor Ring 5. In some embodiments, Q is RQ. In some embodiments, Q is Ring 5. In some embodiments, provided herein is a method of inhibiting PIP4K using a compound of Formula (I’), (I), (II), or (III), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), or (II-g).

[0216] Representative examples of cancers includes adrenocortical carcinoma, AIDS- related cancers (e.g., Kaposi’s and AIDS-related lymphoma), appendix cancer, childhood cancers (e.g., childhood cerebellar astrocytoma, childhood cerebral astrocytoma), basal cell carcinoma, skin cancer (non-melanoma), biliary cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, brain cancer (e.g., gliomas and glioblastomas such as brain stem glioma, gestational trophoblastic tumor glioma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma), breast cancer (e.g., triple negative breast cancer), bronchial adenomas / carcinoids, carcinoid tumor, nervous system cancer (e.g., central nervous system cancer, central nervous system lymphoma), cervical cancer, chronic myeloproliferative disorders, colorectal cancer (e.g., colorectal carcinoma, colorectal carcinoma with microsatellite instability (MSI), colorectal carcinoma that is microsatellite stable (MSS), colon cancer, rectal cancer), lymphoid neoplasm, mycosis fungoids, Sezary Syndrome, endometrial cancer, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell 268 ny-2730225220232001540 tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastrointestinal cancer (e.g., gastric cancer, stomach cancer, small intestine cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST)), cholangiocarcinoma, germ cell tumor, ovarian germ cell tumor, head and neck cancer, neuroendocrine tumors, Hodgkin’s lymphoma, Ann Arbor stage III and stage IV childhood Non-Hodgkin’s lymphoma, ROS1-positive refractory Non-Hodgkin’s lymphoma, leukemia, lymphoma, multiple myeloma, hypopharyngeal cancer, intraocular melanoma, ocular cancer, islet cell tumors (endocrine pancreas), renal cancer (e.g., Wilm’s Tumor, renal cell carcinoma), liver cancer, lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), ALK-positive anaplastic large cell lymphoma, ALK-positive advanced malignant solid neoplasm, Waldenstrom’s macroglobulinema, melanoma, intraocular (eye) melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia (MEN), myelodysplastic syndromes, myelodysplastic / myeloproliferative diseases, nasopharyngeal cancer, neuroblastoma, oral cancer (e.g., mouth cancer, lip cancer, oral cavity cancer, tongue cancer, oropharyngeal cancer, throat cancer, laryngeal cancer), ovarian cancer (e.g., ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor), pancreatic cancer, pancreatic ductal adenocarcinoma, islet cell pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma, metastatic anaplastic thyroid cancer, undifferentiated thyroid cancer, papillary thyroid cancer, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, uterine cancer (e.g., endometrial uterine cancer, uterine sarcoma, uterine corpus cancer), squamous cell carcinoma (e.g., head and neck squamous cell carcinoma), testicular cancer, thymoma, thymic carcinoma, thyroid cancer, juvenile xanthogranuloma, transitional cell cancer of the renal pelvis and ureter and other urinary organs, urethral cancer, gestational trophoblastic tumor, vaginal cancer, vulvar cancer, hepatoblastoma, rhabdoid tumor, and Wilms tumor..

[0217] In some embodiments, the cancer is Hodgkin lymphoma or Non-Hodgkin Lymphoma, for example small lymphocytic lymphoma, Lymphoplasmacytic lymphoma, Burkitt lymphoma, Diffuse large B-cell lymphoma (DLBCL), Marginal zone Lymphoma, Follicular lymphoma, Hairy cell leukemia, and plasma cell neoplasms such as plasmacytoma and Multiple myeloma. See Hematology Reports. 2024; 16(1):164-178.

[0218] In some embodiments, the cancer is acute myeloid leukemia. 269 ny-2730225220232001540

[0219] Compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, treat sarcomas including soft tissue and bone cancers, representative examples of which include osteosarcoma or osteogenic sarcoma (bone) (e.g., Ewing’s sarcoma), chondrosarcoma (cartilage), leiomyosarcoma (smooth muscle), rhabdomyosarcoma (skeletal muscle), mesothelial sarcoma or mesothelioma (membranous lining of body cavities), fibrosarcoma (fibrous tissue), angiosarcoma or hemangioendothelioma (blood vessels), liposarcoma (adipose tissue), glioma or astrocytoma (neurogenic connective tissue found in the brain), myxosarcoma (primitive embryonic connective tissue), mesenchymous or mixed mesodermal tumor (mixed connective tissue types), and histiocytic sarcoma (immune cancer). In some embodiments, provided is a method of treating a sarcoma in a subject in need thereof, comprising administering (a) a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I- ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to the subject. In some embodiments, provided is a method of treating sarcoma in a subject in need thereof, comprising administering a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), 270 ny-2730225220232001540 (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the subject.

[0220] In some embodiments, provided are methods of treating subjects having cell proliferative a disease or disorder of the hematological system, liver, brain, lung, colon, pancreas, prostate, ovary, breast, skin, or endometrium.

[0221] In some embodiments, provided herein are methods of treating subjects having a disease or disorder related to loss-of-function mutations of the phosphoinositide phosphatase FIG4. In some embodiments, the disease or disorder is selected from unis-Varón Syndrome, Charcot-Marie-Tooth, Charcot-Marie-Tooth Type 4J, polymicrogyria with epilepsy, and pediatric neurodegeneration with hypomyelination. In some embodiments, the disease or disorder is Charcot-Marie-Tooth. In some embodiments, the disease or disorder is Charcot- Marie-Tooth Type 4J. See Cao X, Lenk GM, Meisler MH. Altered phenotypes due to genetic interaction between the mouse phosphoinositide biosynthesis genes Fig4 and Pip4k2c. G3 (Bethesda). 2023 Aug 9;13(8):jkad007. doi: 10.1093 / g3journal / jkad007. PMID: 36691351; PMCID: PMC10411592.

[0222] The compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing is administered to a patient as a monotherapy or by way of combination therapy. In some embodiments, the compound is administered to a patient who has received another therapy, such as chemotherapy, radioimmunotherapy, surgical therapy, immunotherapy, radiation therapy, or targeted therapy, or any combination or combinations thereof.

[0223] The methods of the present invention may entail administration of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II- c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing or pharmaceutical compositions thereof to the patient in a single dose or in multiple doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, or more doses). For example, 271 ny-2730225220232001540 the frequency of administration may range from once a day up to about once every eight weeks. In some embodiments, the compound is administered from about once a day. In other embodiments, the compound is administered twice a day (BID).

[0224] In some embodiments, use of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament is provided. In some embodiments, the use is for the manufacture of a medicament for a disease or disorder as disclosed herein.

[0225] In some embodiments, use of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for use in treatment is provided. In some embodiments, the use is for treatment of a disease or disorder as disclosed herein. In some embodiments, the use is for a method as disclosed herein.

[0226] In some embodiments, a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I- l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I- ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for use in treatment is provided. In some embodiments, the compound is for use in treatment of a disease or disclosure as disclosed herein. In some embodiments, the compound is for use in a method as disclosed herein. Combination Therapy

[0227] The compounds of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I- p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I- ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), 272 ny-2730225220232001540 (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing may be used in combination with, or concurrently with, at least one other active agent, e.g., an anti-cancer agent or regimen.

[0228] In some embodiments, the treatment may include administration of a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I- d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II- c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV- j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in combination with one or more additional therapeutics known for use in treating the disease or condition (e.g., cancer). Representative examples of additional active agents and treatment regimens include radiation therapy, chemotherapeutics, immunomodulators, therapeutic antibodies, and CAR-T therapy. Pharmaceutical Kits

[0229] The compounds and their pharmaceutically acceptable salts and stereoisomers and / or compositions comprising them may be assembled into kits or pharmaceutical systems. Kits or pharmaceutical systems according to this aspect of the invention include a carrier or package such as a box, carton, tube or the like, having in close confinement therein one or more containers, such as vials, tubes, ampoules, or bottles, which contain a compound of Formula (I’), (I), (II), (III), (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I- u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag) (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutical composition thereof. The kits or pharmaceutical systems of the invention may also include printed instructions for using the compounds and compositions. In one aspect, a kit comprises a compound of the disclosure or a pharmaceutically acceptable salt thereof, and a label and / or instructions for use of the compound in the treatment of a disease or disorder described herein. The kit may comprise a unit dosage form of the compound. 273 ny-2730225220232001540 Enumerated Embodiments

[0230] The following enumerated embodiments are representative of some aspects of the invention.

[0231] Enumerated Embodiment 1. A compound of Formula (I) ,or a tautomer or or a salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; V is a bond, -C1-4alkylene-, -C(O)-, -C1-4alkylene-C(O)-#, -C(O)N(RV)-#, - N(RV)C(O)-#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Ring 5, wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5bor Q is of, (i) 274 ny-2730225220232001540 wherein:of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6 alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and 275 ny-2730225220232001540 L3is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1- 10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n- C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide, or 276 ny-2730225220232001540 (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.

[0232] Enumerated Embodiment 2. The compound of Enumerated Embodiment 1, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: Ring 1 is a 4- to 8-membered cycloalkyl, saturated 4- to 8-membered heterocyclyl comprising at least one annular ether, saturated 4- to 8-membered heterocyclyl comprising at least one annular amine, or saturated 4- to 8-membered heterocyclyl comprising an annular amide, each of which is optionally substituted with one or more R1; and wherein: (i) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is -C(O)- or -C1-4alkylene-C(O)-#, wherein # indicates the point of attachment to Ring 1; (ii) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amide, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is a bond or -C1-4alkylene-; and (iii) when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, each of which is optionally substituted with one or more R1, then: (a) V is -C(O)N(RV)-#, -N(RV)C(O)-#, -C1-4alkylene-C(O)N(RV)-# or -C1- 4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; or (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5; or (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. 277 ny-2730225220232001540

[0233] Enumerated Embodiment 3. The compound of Enumerated Embodiment 1 or 2, wherein R is chloro.

[0234] Enumerated Embodiment 4. The compound of Enumerated Embodiment 1 or 2, wherein R is fluoro.

[0235] Enumerated Embodiment 5. The compound of any one of Enumerated Embodiments 1-4, wherein Ring 3 is 4- to 6-membered heterocyclyl optionally substituted with one or more R3a.

[0236] Enumerated Embodiment 6. The compound of Enumerated Embodiment 5, wherein Ring 3 is , each ofwhich is optionally substituted with one or more R3a.

[0237] Enumerated Embodiment 7. The compound of any one of Enumerated Embodiments 1-4, wherein Ring 3 is phenyl optionally substituted with one or more R3b.

[0238] Enumerated Embodiment 8. The compound of any one of Enumerated Embodiments 1-4, wherein Ring 3 is 5- to 6-membered heteroaryl optionally substituted with one or more R3b

[0239] Enumerated Embodiment 9. The compound of EnumeratedEmbodiment 8, wherein Ring 3 is , , each of which is optionally substituted with one or more R3b.

[0240] Enumerated Embodiment 10. The compound of any one of Enumerated Embodiments 1-7, wherein Ring 4 is absent.

[0241] Enumerated Embodiment 11. The compound of any one of Enumerated Embodiments 1-7, wherein Ring 4 is 3- to 6-membered cycloalkyl.

[0242] Enumerated Embodiment 12. The compound of Enumerated Embodiment 11, wherein Ring 4 is cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more R4a. 278 ny-2730225220232001540

[0243] Enumerated Embodiment 13. The compound of any one of Enumerated Embodiments 1-9, wherein Ring 4 is 4- to 6-membered heterocyclyl optionally substituted with one or more R4a.

[0244] Enumerated Embodiment 14. The compound of Enumerated Embodiment 13, wherein Ring 4 is , each of which is optionally substitutedwith one or more R4a.

[0245] Enumerated Embodiment 15. The compound of any one of Enumerated Embodiments 1-9, wherein Ring 4 is phenyl optionally substituted with one or more R4b.

[0246] Enumerated Embodiment 16. The compound of any one of Enumerated Embodiments 1-9, wherein Ring 4 is 5- to 6-membered heteroaryl optionally substituted with one or more R4b.

[0247] Enumerated Embodiment 17. The compound of Enumerated Embodiment 16, wherein Ring 4

[0248] Enumerated Embodiment 18. The compound of any one of Enumerated Embodiments 1-4, wherein Ring 3 is phenyl optionally substituted by R3b, and Ring 4 is phenyl optionally substituted by R4b.

[0249] Enumerated Embodiment 19. The compound of any one of Enumerated Embodiments 1-4, wherein Ring 3 is phenyl optionally substituted by R3b, or Ring 4 is phenyl optionally substituted by R4b.

[0250] Enumerated Embodiment 20. The compound of any one of Enumerated Embodiments 1-4, wherein Ring 3 is selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6-membered heterocyclyl optionally substituted with one or more R3a, and 5- to 6-membered heteroaryl optionally substituted with one or more R3b; and 279 ny-2730225220232001540 Ring 4 is selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b.

[0251] Enumerated Embodiment 21. The compound of any one of Enumerated Embodiments 1-9 or 13-20, wherein Ring ,each of whi1ch is optionally substituted with one or more R , wherein # indicates attachment to V.

[0252] Enumerated Embodiment 22. The compound of Enumerated Embodiment 21, wherein Ring 1 is, each of which is optionally substituted with one or more R1; and V is -C(O)N(RV)-, -N(RV)C(O)-, -C1-4alkylene-C(O)N(RV)-#, or -C1-4alkylene- N(RV)C(O)-#, wherein ## indicates the point of attachment to Ring 1.

[0253] Enumerated Embodiment 23. The compound of Enumerated Embodiment 21, whereinRing 1 is or each of which is optionally substituted with one or more R1, wherein # indicates attachment to V; and V is -C(O)- or -C1-4alkylene-C(O)-#, wherein # indicates attachment to Ring 1. 280 ny-2730225220232001540

[0254] Enumerated Embodiment 23-1 The compound of Enumerated Embodiment **, wherein or moreV is bond or -C1-4alkylene-.

[0255] Enumerated Embodiment 24. The compound of any one of Enumerated Embodiments 1-9 or 13-23, wherein Q is RQ.

[0256] Enumerated Embodiment 25. The compound of Enumerated Embodiment 24, wherein RQis H, methyl, or acetyl.

[0257] Enumerated Embodiment 26. The compound of any one of Enumerated Embodiments 1-9 or 13-23, wherein Q is Ring 5 and the compound is of Formula (II):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0258] Enumerated Embodiment 27. The compound of any one of Enumerated Embodiments 1-9 or 13-23, wherein Q is of Formula (i) and the compound is of Formula (IV):, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0259] Enumerated Embodiment 28. The compound of Enumerated Embodiment 27,wherein Ring A is , optionally substituted with C1-4alkyl or halo.

[0260] Enumerated Embodiment 29. The compound of Enumerated Embodiment 27 or 28, wherein X is a bond or -NH-. 281 ny-2730225220232001540

[0261] Enumerated Embodiment 30. The compound of any one of Enumerated Embodiments 27-29, wherein Ring , each of which is optionallyC1-4alkyl.

[0262] Enumerated Embodiment 31. The compound of any one of Enumerated Embodiments 27-30, wherein W is a bond or -O-.

[0263] Enumerated Embodiment 32. The compound of any one of Enumerated Embodiments 27-31, wherein Ring C is absent.

[0264] Enumerated Embodiment 33. The compound of any one of Enumerated Embodiments 27-31, wherein Ring C is, each of which is optionally substituted with one or more RC.

[0265] Enumerated Embodiment 34. The compound of any one of Enumerated Embodiments 27-33, wherein Linker is a bond, C1-10alkylene, or C(O)C1-10alkylene.

[0266] Enumerated Embodiment 35. The compound of any one of Enumerated Embodiments 27-34, wherein Ring 2 is present and U is a bond.

[0267] Enumerated Embodiment 36. The compound of any one of Enumerated Embodiments 27-35, wherein Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a.

[0268] Enumerated Embodiment 37. The compound of any one of EnumeratedEmbodiments 27-36, wherein Ring 2 is , , , or 282 ny-2730225220232001540 of which is optionally substituted with one or more R2a, wherein #indicates attachment to V.

[0269] Enumerated Embodiment 38. The compound of any one of Enumerated Embodiments 27-36, wherein Ring 2 is , each ofwhich is optionally substituted with one or more wherein # indicates attachment to V.

[0270] Enumerated Embodiment 39. The compound of Enumerated Embodiment 38, wherein Ring 2

[0271] Enumerated Embodiment 40. The compound of Enumerated Embodiment 39, wherein V is -C(O)- and Ring 1 is

[0272] Enumerated Embodiment 41. The compound of Enumerated Embodiment 37,, each of which is optionally substituted with one or more R2a, wherein # indicates attachment to V.

[0273] Enumerated Embodiment 42. The compound of Enumerated Embodiment 41, wherein V is -C(O)- and Ring 1 is cyclohexyl.

[0274] Enumerated Embodiment 43. The compound of Enumerated Embodiment 41, wherein V is -C1-4alkyl-C(O)- and Ring 1 is piperidinyl.

[0275] Enumerated Embodiment 44. The compound of any one of Enumerated 1, , or .

[0276] Enumerated Embodiment 45. The compound Enumerated Embodiment 44, wherein Ring, , 283 ny-2730225220232001540 ,

[0277] 1, wherein the compound is selected from the compounds provided in Table 1 and Table 2, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0278] Enumerated Embodiment 47. The compound of Enumerated Embodiment 46, wherein the compound is selected from the compounds provided in Table 1, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0279] Enumerated Embodiment 48. The compound of Enumerated Embodiment 46, wherein the compound is selected from the compounds provided in Table 2, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0280] Enumerated Embodiment 49. A pharmaceutical composition, comprising a compound of any one of Enumerated Embodiments 1-48, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient.

[0281] Enumerated Embodiment 50. The pharmaceutical composition of Enumerated Embodiment 49, wherein the compound is a compound of any one of Enumerated Embodiments 24-26 or 47, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient.

[0282] Enumerated Embodiment 51. The pharmaceutical composition of Enumerated Embodiment 49, wherein the compound is a compound of any one of Enumerated Embodiments 27-45 or 48, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient.

[0283] Enumerated Embodiment 52. A method of treating a disease or disorder associated with PIP4K2C, comprising administering to a subject a compound of any of Enumerated Embodiments 1-48, or the pharmaceutical composition of Enumerated Embodiment 49.

[0284] Enumerated Embodiment 53. A method of treating a disease or disorder by modulating the level or activity of PIP4K2C, comprising administering to a subject a compound of any of Enumerated Embodiments 1-48, or a tautomer or stereoisomer thereof, 284 ny-2730225220232001540 or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of Enumerated Embodiment 49.

[0285] Enumerated Embodiment 54. The method of Enumerated Embodiment 53, wherein the method modulates the activity of PIP4K2C, and wherein the method comprises administering to the subject a compound of any of Enumerated Embodiments 24-26 or 47, or a tautomer or stereoisomer thereof, or a pharmaceutically acce...

Claims

220232001540 CLAIMS What is claimed is: Claim 1. A compound of Formula (I’)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R is halo; Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b; Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b; Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1; V is a bond, -C1-4alkylene-, -C(O)-, -C(O)O-#, -OC(O)# -C1-4alkylene-C(O)-#, - C(O)N(RV)-#, -N(RV)C(O)-#, -OC(O)N(RV)-#, -N(RV)-C(O)O#, -C1-4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and Q is RQ, or Ring 5, wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b; or Q is of Formula (i)wherein: 1426 ny-2730225220232001540 Ring A is selected from the group consisting, each of which is optionally substituted with one or more C1-4alkyl or halo; X is a bond, -O-, -NH-, or -NHC(O)-;which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RDis H or C1-4alkyl, wherein # indicates attachment to X; W is a bond, -O-, -NH-, or -NHC(O)-; Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC; Linker is a bond, -O-, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and ** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent; L1is a bond or C1-6alkylene; L2is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and 1427 ny-2730225220232001540 L3is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)-C1-10alkylene, C(O)-C1- 10alkylene-N(Ry), C(O)N(Ry)-C1-10alkylene, or C(O)N(Ry)-C1-10alkylene-N(Ry); U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present; Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b; each R1is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(R,z), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O- C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RCis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RLis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; each RQis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each RVis independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl; each Rwis independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl; each Rxis independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and each n is independently 0, 1, or 2; 1428 ny-2730225220232001540 wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide or carbamate, or (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide or carbamate; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; and when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is -OC(O)#, then RQis not tert-butyl. Claim 2. The compound of claim 1, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: V is a bond, -C1-4alkylene-, -C(O)-, -C1-4alkylene-C(O)-#, -C(O)N(RV)-#, -N(RV)C(O)-#, -C1- 4alkylene-C(O)N(RV)-# or -C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)-C1-10alkylene, C1-6alkylene-C(O)N(Ry)-C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, each R2a, R3a, R4a, and R5ais independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; each R2b, R3b, R4b, and R5bis independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O-C1-4alkyl, C1-4alkylene- N(Ry)-C1-4alkyl, or C1-4alkylene-S(O)nRx; each RVis independently halo, OH, C1-4alkyl, or C1-4haloalkyl; 1429 ny-2730225220232001540 each Ryand Rzis independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O-C1-4alkyl, C1-4alkylene-NH-C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n- C1-4alkyl; and each n is independently 0, 1, or 2; wherein: (a) Ring 1 comprises an intraannular amide, or (b) V comprises an amide, or (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide; and wherein: when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; and when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is -OC(O)#, then RQis not tert-butyl. Claim 3. The compound of claim 1 or 2, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: Ring 1 is a 4- to 8-membered cycloalkyl, saturated 4- to 8-membered heterocyclyl comprising at least one annular ether, saturated 4- to 8-membered heterocyclyl comprising at least one annular amine, or saturated 4- to 8-membered heterocyclyl comprising an annular amide, each of which is optionally substituted with one or more R1; and wherein: (i) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is -C(O)- or -C1-4alkylene-C(O)-#, wherein # indicates the point of attachment to Ring 1; (ii) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amide, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is a bond or -C1-4alkylene-; and (iii) when Ring 1 is C4-8cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, each of which is optionally substituted with one or more R1, then: 1430 ny-2730225220232001540 (a) V is -C(O)N(RV)-#, -N(RV)C(O)-#, -C1-4alkylene-C(O)N(RV)-# or -C1- 4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; or (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 5; or (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is -C(O)- and is attached to an annular nitrogen atom of Ring 2. Claim 4. The compound of any of claims 1-3, wherein R is chloro. Claim 5. The compound of any of claims 1-3, wherein R is fluoro. Claim 6. The compound of any of claims 1-5, wherein Ring 3 is 4- to 6-membered heterocyclyl optionally substituted with one or more R3a. Claim 7. The compound of claim 6, wherein Ring 3 is, or, each of which is optionally substituted with one or more R3a. Claim 8. The compound of any of claims 1-5, wherein Ring 3 is phenyl optionally substituted with one or more R3b. Claim 9. The compound of any of claims 1-5, wherein Ring 3 is 5- to 6-membered heteroaryl optionally substituted with one or more R3bClaim 10. The compound of claim 9, wherein Ring 3 is, , each of which is optionally substituted with one or more R3b. Claim 11. The compound of any of claims 1-8, wherein Ring 4 is absent. Claim 12. The compound of any of claims 1-8, wherein Ring 4 is 3- to 6-membered cycloalkyl. 1431 ny-2730225220232001540 Claim 13. The compound of claim 12, wherein Ring 4 is cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more R4a. Claim 14. The compound of any of claims 1-10, wherein Ring 4 is 4- to 6-membered heterocyclyl optionally substituted with one or more R4a. Claim 15. The compound of claim 14, wherein Ring 4 is, each of which is optionally substituted with one or more R4a. Claim 16. The compound of any of claims 1-10, wherein Ring 4 is phenyl optionally substituted with one or more R4b. Claim 17. The compound of any of claims 1-10, wherein Ring 4 is 5- to 6-membered heteroaryl optionally substituted with one or more R4b. Claim 18. The compound of claim 17, wherein Ring 4 isoptionally substituted with one or more R4b. Claim 19. The compound of any of claims 1-5, wherein Ring 3 is phenyl optionally substituted by R3b, and Ring 4 is phenyl optionally substituted by R4b. Claim 20. The compound of any of claims 1-5, wherein Ring 3 is phenyl optionally substituted by R3b, or Ring 4 is phenyl optionally substituted by R4b. Claim 21. The compound of any of claims 1-5, wherein Ring 3 is selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6-membered heterocyclyl optionally substituted with one or more R3a, and 5- to 6-membered heteroaryl optionally substituted with one or more R3b; and 1432 ny-2730225220232001540 Ring 4 is selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b. Claim 22. The compound of any of claims 1-10 or 14-21, wherein Ring 1 is,substituted with one or more R1, wherein # indicates attachment to V. Claim 23. The compound of claim 22, wherein Ring, each of which is optionally substituted with one or more R1; and V is -C(O)N(RV)-, -N(RV)C(O)-, -C1-4alkylene-C(O)N(RV)-#, or -C1-4alkylene- N(RV)C(O)-#, wherein ## indicates the point of attachment to Ring 1. Claim 24. The compound of claim 22, wherein Ringeach of which is optionally substituted with one or more R1, wherein # indicates attachment to V; and V is -C(O)- or -C1-4alkylene-C(O)-#, wherein # indicates attachment to Ring 1. Claim 25. The compound of claim 22, wherein Ring, each of which is optionally substituted with one or more R1, wherein # indicates attachment to V; and V is bond or -C1-4alkylene-. 1433 ny-2730225220232001540 Claim 26. The compound of any of claims 1-10 or 14-25, wherein Q is RQ. Claim 27. The compound of claim 26, wherein RQis H, methyl, or acetyl. Claim 28. The compound of any of claims 1-10 or 14-25, wherein Q is Ring 5 and the compound is of Formula (II):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Claim 29. The compound of any of claims 1-10 or 14-25, wherein Q is of Formula (i) and the compound is of Formula (IV):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Claim 30. The compound of claim 29, wherein Ring A is, optionally substituted with C1-4alkyl or halo. Claim 31. The compound of claim 29 or 30, wherein X is a bond or -NH-. 1434 ny-2730225220232001540 Claim 32. The compound of any of claims 29-31, wherein Ring B is ,,, each of which is optionally substituted with one or more halo or OH, wherein RDis H or C1-4alkyl. Claim 33. The compound of any of claims 29-32, wherein W is a bond or -O-. Claim 34. The compound of any of claims 29-33, wherein Ring C is absent. Claim 35. The compound of any of claims 29-33, wherein Ring C is,each of which is optionally substituted with one or more RC. Claim 36. The compound of any of claims 29-35, wherein Linker is a bond, C1-10alkylene, or C(O)C1-10alkylene. Claim 37. The compound of any of claims 29-36, wherein Ring 2 is present and U is a bond. Claim 38. The compound of any of claims 29-37, wherein Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a. Claim 39. The compound of any of claims 1-23 or 26-38, wherein RVis H. Claim 40. The compound of any of claims 29-37 or 39, wherein Ring 2 is 3- to 10- membered cycloalkyl optionally substituted with one or more R2a. 1435 ny-2730225220232001540 Claim 41. The compound of any of claims 29-39, wherein Ring 2 is,each of which is optionally substituted with one or more R2a, wherein # indicates attachment to V. Claim 42. The compound of any of claims 29-39 or 41, wherein Ring 2 is,each of which is optionally substituted with one or more R2a, wherein # indicates attachment to V. Claim 43. The compound of claim 42, wherein Ring 2 is. Claim 44. The compound of claim 43, wherein V is -C(O)- and Ring 1 is piperidinyl. Claim 45. The compound of claim 41 or 42, wherein Ring, each of which is optionally substituted with one or more R2a, wherein # indicates attachment to V. Claim 46. The compound of claim 45, wherein V is -C(O)- and Ring 1 is cyclohexyl. Claim 47. The compound of claim 45, wherein V is -C1-4alkyl-C(O)- and Ring 1 is piperidinyl. Claim 48. The compound of any of claims 27-35, wherein Ring 2, V, and Ring 1 are taken together to form: 1436 ny-2730225220232001540Claim 49. The compound of claim 48, wherein Ring 2, V, and Ring 1 are taken together to form: ,. Claim 50. The compound of claim 40, wherein Ring 2 is cyclohexyl optionally substituted with one or more R2a. Claim 51. The compound of claim 50, wherein Ring 2 isoptionally substituted with one or more R2a. Claim 52. The compound of claim 50 or 51, wherein V is -C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1, and wherein Ring 1 is cyclohexyl. Claim 53. The compound of any of claims 50-52, wherein Ring 2, V, and Ring 1 are takenClaim 54. The compound of claim 1, wherein the compound is selected from the compounds provided in Table 1 and Table 2, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 1437 ny-2730225220232001540 Claim 55. The compound of claim 54, wherein the compound is selected from the compounds provided in Table 1, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Claim 56. The compound of claim 54, wherein the compound is selected from the compounds provided in Table 2, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Claim 57. A pharmaceutical composition, comprising a compound of any of claims 1-56, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient. Claim 58. The pharmaceutical composition of claim 57, wherein the compound is a compound of any of claims 26-28 or 55, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient. Claim 59. The pharmaceutical composition of claim 57, wherein the compound is a compound of any of claims 29-53 or 56, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient. Claim 60. A method of treating a disease or disorder associated with PIP4K2C, comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57. Claim 61. A method of treating a disease or disorder by modulating the level or activity of PIP4K2C, comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57. 1438 ny-2730225220232001540 Claim 62. The method of claim 61, wherein the method modulates the activity of PIP4K2C, and wherein the method comprises administering to the subject a compound of any of claims 26-28 or 55, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 58. Claim 63. The method of claim 61, wherein the method modulates the level of PIP4K2C, and wherein the method comprises administering to the subject a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59. Claim 64. The method of any one of claims 60-63, wherein the disease or disorder is a cancer, immune deficiency, autoimmune disease, infectious disease, or a combination thereof. Claim 65. The method of claim 64, wherein the cancer is brain cancer, bladder cancer, breast cancer, triple negative breast cancer, cervical cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, melanoma, Merkel cell carcinoma, multiple myeloma, pancreatic ductal carcinoma, or renal cell carcinoma. Claim 66. The method of claim 65, wherein the cancer is brain cancer, breast cancer, triple negative breast cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, or non-small cell lung cancer. Claim 67. The method of any of claims 60-63, wherein the disease or disorder is a neurodegenerative disease. Claim 68. A method of treating a viral infection by modulating the level of PIP4K2C, comprising administering to a subject a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59. 1439 ny-2730225220232001540 Claim 69. A method of treating necrotizing soft tissue infection (NSTI), comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57. Claim 70. A method of modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57. Claim 71. A compound of any of claims 1-56, or the pharmaceutical composition of claim 57, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for use in treating a disease or disorder associated with PIP4K2C in a subject in need thereof. Claim 72. A compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, for use in treating a disease or disorder by modulating the level or activity of PIP4K2C in a subject in need thereof. Claim 73. The compound for use of claim 72, wherein the compound for use modulates the activity of PIP4K2C, and wherein the compound for use is a compound of any of claims 26- 28 or 55, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 58. Claim 74. The compound for use of claim 72, wherein the compound for use modulates the level of PIP4K2C, and wherein the compound for use is a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59. Claim 75. The compound for use of any one of claims 71-74, wherein the disease or disorder is a cancer, immune deficiency, autoimmune disease, infectious disease, or a combination thereof. 1440 ny-2730225220232001540 Claim 76. The compound for use of claim 75, wherein the cancer is brain cancer, bladder cancer, breast cancer, triple negative breast cancer, cervical cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, melanoma, Merkel cell carcinoma, multiple myeloma, pancreatic ductal carcinoma, or renal cell carcinoma. Claim 77. The compound for use of claim 76, wherein the cancer is brain cancer, breast cancer, triple negative breast cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, or non-small cell lung cancer. Claim 78. The compound for use of any of claims 71-74, wherein the disease or disorder is a neurodegenerative disease. Claim 79. A compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59, for use in treating a viral infection by modulating the level of PIP4K2C in a subject in need thereof. Claim 80. A compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, for use in treating necrotizing soft tissue infection (NSTI) in a subject in need thereof. Claim 81. A compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, for use in modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C in a subject in need thereof. Claim 82. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a 1441 ny-2730225220232001540 medicament for treating a disease or disorder associated with PIP4K2C in a subject in need thereof. Claim 83. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for treating a disease or disorder by modulating the level or activity of PIP4K2C in a subject in need thereof. Claim 84. The use of claim 83, wherein the use modulates the activity of PIP4K2C, and wherein the compound is a compound of any of claims 26-28 or 55, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Claim 85. The use of claim 83, wherein the use modulates the level of PIP4K2C, and wherein the compound is a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Claim 86. The use of any one of claims 82-85, wherein the disease or disorder is a cancer, immune deficiency, autoimmune disease, infectious disease, or a combination thereof. Claim 87. The use of claim 86, wherein the cancer is brain cancer, bladder cancer, breast cancer, triple negative breast cancer, cervical cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, melanoma, Merkel cell carcinoma, multiple myeloma, pancreatic ductal carcinoma, or renal cell carcinoma. Claim 88. The use of claim 87, wherein the cancer is brain cancer, breast cancer, triple negative breast cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, or non-small cell lung cancer. Claim 89. The use of any of claims 82-85, wherein the disease or disorder is a neurodegenerative disease. 1442 ny-2730225220232001540 Claim 90. Use of a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for treating a viral infection by modulating the level of PIP4K2C in a subject in need thereof. Claim 91. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for treating necrotizing soft tissue infection (NSTI) in a subject in need thereof. Claim 92. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C in a subject in need thereof. Claim 93. A kit, comprising (i) a compound of any of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, and (ii) instructions for use in treating an PIP4K- mediated disease, disorder, or condition in an individual in need thereof. Claim 94. The method of claim 65 or 66, wherein the cancer is brain cancer. Claim 95. The method of any of claims 65, 66, or 94 wherein the brain cancer is glioma or glioblastoma. Claim 96. The method of any of claims 65, 66, or 94, wherein the brain cancer is brain stem glioma, gestational trophoblastic tumor glioma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, or visual pathway or hypothalamic glioma. Claim 97. The method of claim 65 or 66, wherein the cancer is colorectal cancer. Claim 98. The method of any of claims 65, 66, or 97, wherein the colorectal cancer is colorectal carcinoma, colorectal carcinoma with MSI, or colorectal carcinoma with MSS. 1443 ny-2730225220232001540 Claim 99. The method of any of claims 65, 66, or 97, wherein the colorectal cancer is associated with a hereditary syndrome. Claim 100. The method of claim 65 or 66, wherein the cancer is non-small cell lung cancer. Claim 101. The compound for use of claim 76 or 77, wherein the cancer is brain cancer. Claim 102. The compound for use of any of claims 76, 77, or 101, wherein the brain cancer is glioma or glioblastoma. Claim 103. The compound for use of any of claims 76, 77, or 101, wherein the brain cancer is brain stem glioma, gestational trophoblastic tumor glioma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, or visual pathway or hypothalamic glioma. Claim 104. The compound for use of claim 76 or 77, wherein the cancer is colorectal cancer. Claim 105. The compound for use of any of claims 76, 77, or 104, wherein the colorectal cancer is colorectal carcinoma, colorectal carcinoma with MSI, or colorectal carcinoma with MSS. Claim 106. The compound for use of any of claims 76, 77, or 104, wherein the colorectal cancer is associated with a hereditary syndrome. Claim 107. The compound for use of claim 76 or 77, wherein the cancer is non-small cell lung cancer. Claim 108. The use of claim 87 or 88, wherein the cancer is brain cancer. Claim 109. The use of any of claims 87, 88, or 108, wherein the brain cancer is glioma or glioblastoma. Claim 110. The use of any of claims 87, 88, or 108, wherein the brain cancer is brain stem glioma, gestational trophoblastic tumor glioma, cerebellar astrocytoma, cerebral 1444 ny-2730225220232001540 astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, or visual pathway or hypothalamic glioma. Claim 111. The use of claim 87 or 88, wherein the cancer is colorectal cancer. Claim 112. The use of claim 87, 88, or 111, wherein the colorectal cancer is colorectal carcinoma, colorectal carcinoma with MSI, or colorectal carcinoma with MSS. Claim 113. The use of claim 87, 88, or 111, wherein the colorectal cancer is associated with a hereditary syndrome. Claim 114. The use of claim 87 or 88, wherein the cancer is non-small cell lung cancer. Claim 115. The method of any one of claims 60-63, wherein the disease or disorder is related to loss-of-function mutations of the phosphoinositide phosphatase FIG4. Claim 116. The method of claim 115, wherein the disease or disorder is Charcot-Marie- Tooth. Claim 117. The method of claim 115 or 116, wherein the disease or disorder is Charcot- Marie-Tooth Type 4J. Claim 118. The compound for use of any one of claims 71-74, wherein the disease or disorder is related to loss-of-function mutations of the phosphoinositide phosphatase FIG4. Claim 119. The compound for use of claim 118, wherein the disease or disorder is Charcot- Marie-Tooth. Claim 120. The compound for use of claim 118 or 119, wherein the disease or disorder is Charcot-Marie-Tooth Type 4J. Claim 121. The use of any one of claims 82-85, wherein the disease or disorder is related to loss-of-function mutations of the phosphoinositide phosphatase FIG4. Claim 122. The use of claim 121, wherein the disease or disorder is Charcot-Marie-Tooth. 1445 ny-2730225220232001540 Claim 123. The use of claim 121 or 122, wherein the disease or disorder is Charcot-Marie- Tooth Type 4J. Claim 124. The method of claim 68, wherein the compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with a vaccine for viral infections to enhance the immune response. Claim 125. The compound for use of claim 79, wherein the compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with a vaccine for viral infections to enhance the immune response. Claim 126. The use of claim 90, wherein the medicament is administered in combination with a vaccine for viral infections to enhance the immune response. 1446 ny-2730225